RUSNANO News Sat, 29 Jul 2017 02:52:33 +0300 RUSNANO Successfully Quitted NIR Company <h5>RUSNANO has completed the transaction of sale of 49.98% of shares in &ldquo;New Instrumental Solutions&rdquo; Closed Joint-Stock Company (NIR, CJSC) to NPO &ldquo;Saturn&rdquo;. IRR of the transaction has made more than 26%.</h5> <p>NIR was put into operation in 2010 in Rybinsk, the Yaroslav Region, and became the first plant opened under the auspices of RUSNANO. Solid-cast instrument with multilayer nanostructured coating produced by that company is unique in Russia. NIR products allowed to substitute the imported instrument, which was previously used in the Russian industry for processing of various materials, with innovative domestic product.</p> <p>The areas of application are hi-tech segments of domestic industry (jet engine building, rocket-and-space industry, instrument-making, etc.). The nanostructured coating, the application of which was developed by scientists of the Researchers at the Kurchatov Institute, increases wear resistance of the tools by 2-2.5 times, and prolongs the periods between regrindings and the speed of cutting by 1.5-2 times.</p> <p>The production capacity of the enterprise is 13,000 instruments per month. More than 100 workplaces were created within the project. From the moment when RUSNANO joined the project, the profit of NIR increased regularly. In 2016, it made RUR 340 mln, which exceeds the figures of 2015 by 30%.</p> <p>&ldquo;In the recent years, NIR became one of the leaders in the sphere that is vital for the country. I am completely satisfied with the project, with the management team of the plant and with our partners from NPO &lsquo;Saturn&rsquo; and the United Engine-Building Corporation&rdquo;, noted the managing director for the investment activity of MC RUSNANO, <strong>Andrey Gorkov</strong>.</p> Wed, 31 May 2017 12:00:00 +0300 PET-Technology, RUSNANO’s Portfolio Company, Opened Nuclear Medicine Center in Yekaterinburg <p>The opening ceremony of the Positron Emission Computed Tomography (PET/CT) Center of PET-Technology, RUSNANO&rsquo;s portfolio company, took place in Yekaterinburg. The event was attended by the Governor of the Sverdlovsk Region <strong>Evgeny Kuivashev</strong>, Deputy Chairman of RUSNANO <strong>German Pikhoya</strong>, Managing Director for the Investment Activity of RUSNANO <strong>Olga Shpichko</strong>, Managing Director for Regional Policy and Interaction with Government Bodies and the Federal Assembly of RUSNANO <strong>Dmitry Krinitsky</strong>, Investment Director of RUSNANO <strong>Andrei Putilov</strong>, First Deputy Chairman of the Government of the Sverdlovsk Region <strong>Vladimir Vlasov</strong>, and Minister of Health of the Sverdlovsk Region <strong>Igor Trofimov</strong>.</p> <p style="text-align: center;"><img alt="PET-Technology, RUSNANO’s Portfolio Company, Opened Nuclear Medicine Center in Yekaterinburg" src="/upload/images/news/2016-06-29_PET_Ekaterinburg_02.jpg" /></p> <p>After a ceremonial tour of the PET Center, there was a meeting attended by the Governor of the Sverdlovsk Region <strong>Evgeny Kuivashev</strong> and Deputy Chairman of RUSNANO <strong>German Pikhoya</strong>. The meeting was focused on the discussion of practical application of the high-tech medical services for diagnostics and treatment of oncology diseases of the people of the Sverdlovsk Region. The meeting participants also discussed the development strategy of the Regional Positron Emission Computed Tomography (PET/CT) Center.</p> <p>Following the meeting, the parties agreed to increase the number, quality and availability of radioisotope diagnostics and treatment for the residents of the Sverdlovsk Region. Furthermore, the agreements were reached for further promotion of the modernisation and retrofit of the PET/CT Center in Yekaterinburg, as well as the establishment of a working group under the Government of the Sverdlovsk Region with the participation of the Ministry of Health of Sverdlovsk Region and the authorities and organisations concerned. The Ministry of Health of the Sverdlovsk Region in cooperation with the Regional Compulsory Medical Insurance Fund will work on increasing the quota for diagnostic procedures in the PET/CT Center. Today, the Regional Compulsory Medical Insurance Fund budget covers the costs of medical tests for up to 6,000 patients annually. PET-Technology will develop and as of September 2016 will start to implement a Training Programme for Radiologists with the possibility of internship in the Nuclear Medicine Center in Yekaterinburg.</p> <p>&ldquo;The opening of the PET Center in Yekaterinburg is another important step in our strategy to create a network of nuclear medicine centers across Russia. Our top priority task is to help the greatest number of people suffering from oncology diseases. The successful treatment of oncology patients depends on the quality of diagnostics. The Positron Emission Computed Tomography allows us to both accurately localise the tumour and also to determine the response of cancerous tissues to the treatment. The opening of the Center will improve the quality of patients&rsquo; treatment and thus save lives,&rdquo; said Deputy Chairman of RUSNANO <strong>German Pikhoya</strong>.</p> <p>&ldquo;The Sverdlovsk Region has managed to achieve significant progress in the development of high-tech medical care. In terms of the level of funding in this sphere, we are ranked second in Russia after Moscow, which gives us an opportunity to conduct large-scale work in the fight against the most dangerous diseases, including cancer. In 2015, the high percentage of early detection of diseases and the effectiveness of treatment allowed the Sverdlovsk Region to become one of few regions in Russia that saw the reduction in the cancer mortality rate. I am sure that by opening the PET Center today we are taking another important step in the development of high-tech medicine. We will improve the quality and effectiveness of the treatment of oncology patients, thus healing and maintaining the health of thousands of the Ural people&rdquo;, said <strong>Evgeny Kuivashev</strong>.</p> <p>Oncology diseases are one of the two major causes of death in Russia. Today, the most modern and accurate diagnostics tool for oncology diseases is the PET/CT scanning. This technology gives us an opportunity to accurately define a treatment strategy for diseases at the earliest stages, control its effectiveness and exclude unnecessary and often expensive treatment methods.</p> <p>The network of PET/CT Centers allows us to make this type of diagnostics accessible for the citizens of many Russian regions.</p> Wed, 29 Jun 2016 12:00:00 +0300 Chad Mirkin Has Been Announced RUSNANOPRIZE Laureate in 2016 <p>In 2016 <a href="" target="_blank">RUSNANOPRIZE Nanotechnology International Prize</a> was awarded to <a href="" target="_blank"><strong>Dr. Mirkin</strong></a> for the development of three-dimensional nucleic acid nanostructures called Spherical Nucleic Acids (SNAs) that are enabling technological advances in biological and medical diagnostics and pharmaceutical development. Nanosphere, Inc.&mdash;awarded for being the first in achieving successful commercialization of three-dimensional nucleic acid nanostructures (Spherical Nucleic Acids, SNAs) in production of Verigene&reg; System instrumentation and many other medical, pharmacological, and biotechnological materials and devices based on SNAs. The prize solemn award ceremony was held within the frameworks of Open Innovation Forum.</p> <div class="img"><img alt="Chad Mirkin Has Been Announced RUSNANOPRIZE Laureate in 2016" src="" /> <p>Dr. Chad Mirkin (in the center) has been announced RUSNANOPRIZE Laureate in 2016</p></div> <p>Essentially, Dr. Mirkin has taught the world that organizing nucleic acids, the most important class of molecules ever studied, into highly oriented, densely packed spherical materials can dramatically change the fundamental chemical and physical properties of such structures and make them extraordinarily useful in the areas spanning biomedicine, pharmacology, and biotechnology, including clinical diagnostics and intracellular gene regulation and immunomodulation. As both the top most cited chemist and nanomedicine researcher in the world, Chad Mirkin has clearly distinguished himself academically, but the ultimate value of his work is being proven by its impact on business and society as well as life itself. Dr. Mirkin&rsquo;s discoveries and inventions, particularly those involving SNAs (nanomaterials which are typically comprised of nanoparticle cores and densely functionalized and highly oriented nucleic acid shells), are rooted in basic science advances, but yet are igniting change across a number of industries from the life sciences to health care.</p> <p>Dr. Mirkin is the inventor on over 1,000 patent applications (288 issued) worldwide. His SNA inventions are at the core of product development at Nanosphere (recently acquired by Luminex) and form the basis of a patent portfolio ranked by 1790 Analytics as number two in the world across all industries behind that of only Hewlett Packard Company. His work and leadership have helped to build Northwestern University into one of the largest nanotechnology centers in the world. Northwestern was selected as one of the six nanoscale science and engineering centers funded by the National Science Foundation and as one of eight nanocancer centers funded by the National Cancer Institute. It should come as no surprise that funding for the Institute now exceeds $800 million, and the companies Mirkin has founded (Nanosphere, AuraSense, AuraSense Therapeutics, and NanoInk) have already garnered over $700 million in private and venture capital from some of the top firms in the industry. To quote Sir Fraser Stoddart, &ldquo;A century ago if you were an artist or writer, Paris was a magnet drawing people. Today, Northwestern is the magnet drawing people in nanotechnology.&rdquo; Mirkin has been the driving force to help make this happen.</p> <p><strong>In 2016 RUSNANOPRIZE is sponsored by Otkritie Financial Corporation Bank.</strong></p> Wed, 26 Oct 2016 12:00:00 +0300 RUSNANO and Power Machines Agree to Cooperate in Localization of Production of Wind Turbine Equipment <h5>RUSNANO and Power Machines PJSC signed a memorandum of understanding under which both companies are interested in the joint implementation of the project (hereinafter, the Project) on production of wind turbines components on the Russian territory. The parties have reached an agreement in principle on the parity financing of the production of wind turbine components.</h5> <p>RUSNANO with potential partners plans to participate in the project on the construction of wind parks, within which a foreign supplier of wind turbines from among the world&#39;s largest vendors will be selected. The joint Project on the production of wind turbine components with Power Machines PJSC is planned to be implemented together with a selected vendor and (or) its OEM-manufacturers. One of the main conditions of the selection of the supplier is the equipment production localization program on the Russian territory. The localization level will increase annually and should reach 65% by 2019.</p> <p>As previously reported, RUSNANO intends to invest in localization projects up to 1 billion RUR. RUSNANO is considering several sites on the territory of Russia to establish the production of wind turbine components within the framework of implementation of the localization plan.</p> <p>Power Machines OJSC is ready to be a Russian technological partner of the Project. It is planned that at the TKZ plant Krasny Kotelshchik in Taganrog (part of Power Machines Group) the production of towers and (optionally) the assembly of gondolas will be organized. The unique competitive advantage of the Project planned to be implemented may be the participation of Severstal. The Parties are discussing terms for the long-term delivery of steel sheets</p> <p>to produce wind turbine towers weighing up to 180 tons each by Severstal. The production of generators for wind turbines at one of Power Machines production sites is also being considered.</p> <p>Power Machines PJSC is a global power engineering company, which is in the top ten industry leaders in terms of the volume of installed equipment. The company produces solutions for thermal, nuclear, hydropower engineering, the electric grid complex, industry and transport.</p> Wed, 26 Apr 2017 12:00:00 +0300 RUSNANO’s Subsidiary Sells Its Stake in American Company Tobira <p>A subsidiary of RUSNANO, RusnanoMedInvest, withdraws from the capital of Tobira Therapeutics, a company developing drugs for the treatment of liver diseases, inflammatory diseases, fibrosis, and HIV infection. The buyer is Allergan, one of the world&rsquo;s largest pharmaceutical companies.</p> <p>&ldquo;We are satisfied with the results of the largest transaction on the global pharmaceutical market. Its results confirm that we have correctly identified life science as a sphere for investment. We will use our proceeds from this transaction, inter alia, for creation of &lsquo;Big Pharma&rsquo; in Russia,&rdquo; said Chairman of the Board of MC RUSNANO <strong>Anatoly Chubais</strong> commenting on the transaction.</p> Wed, 21 Sep 2016 12:00:00 +0300 Vestas Enters Russian Market as Supplier for Fortum Energy Projects Based on the results of the regular annual auction of renewable energy projects, the portfolio company and operator of the Wind Energy Development Fund, created by RUSNANO and Fortum Russia, Fortum Energy, was awarded the right to participate in a series of projects for construction of wind power plants. It is planned that wind power plants with total capacity of up to 1000 MW will be constructed under the projects. <p>Based on the results of the regular annual auction of renewable energy projects, the portfolio company and operator of the Wind Energy Development Fund, created by RUSNANO and Fortum Russia, Fortum Energy, was awarded the right to participate in a series of projects for construction of wind power plants. It is planned that wind power plants with total capacity of up to 1000 MW will be constructed under the projects.</p> <p>Within the partnership, RUSNANO and Fortum on a parity basis intend to invest a total of RUB up to 30 billion in construction of wind power plants in Russia. There are also plans to involve loan project financing for implementation of the projects.</p> <p>Vestas was chosen as the wind turbines supplier by the Fund operator. One of the main conditions for the selection of the wind power plants equipment supplier is availability of the program for local content in manufacturing the equipment in Russia. The local content level will increase annually and should reach 65% by 2019. Vestas plans to develop production of a number of components for wind power plants in Russia.</p> <p>As previously reported, RUSNANO intends to invest in local content projects up to RUB 1 billion (~ &euro; 15 million). The local content projects will be implemented in partnership with Vestas itself, its OEM-partners and Russian technology partners. The investments will be aimed at creating the production of assemblies and components of wind turbines: blades, towers and other components. The listed products will be, among other things, manufactured with nanotechnologies. This project will be the driver for development of related industries (metallurgy, materials science, power engineering, construction, engineering, service), allowing to include Russian enterprises in the global supplier chain and realizing their export potential.</p> Wed, 21 Jun 2017 12:00:00 +0300 RUSNANO Proceeds to Sell Its Share in Novomet <p>RUSNANO announces the start of the open competition for the search for a buyer of its share in the portfolio company Novomet. The minimum price of the block (30.76%) determined by independent assessment is 7.5 billion rubles.</p> <p>Novomet specialises in innovation technologies, from the development of new types of oil extraction equipment to supervising and selecting oil well equipment. The company&rsquo;s main products are electric submersible centrifugal pumping plants. They are some of the best on the world market in terms of reliability and energy consumption, especially when extracting oil in complex deposits and offshore.</p> <p>RUSNANO joined the project in 2011, having invested nearly 4 billion rubles. During this period, Novomet became one of the biggest companies in its segment, ranking second in terms of market share in Russia (20%) and seventh in the world (2.3%).</p> <p>The technological innovation of the project is the use of protective and functional nanostructured coatings of tungsten carbide, with titanium and aluminium oxide, chromium and molybdenum treatment. As a consequence, the energy consumption of Novomet pumps is 20-30% lower than their equivalents and their corrosion and hydroabrasion resistance parameters are 1.5-2 times higher.</p> <p>The company supplies products and renders services to a wide range of Russian and foreign oil companies in 15 countries. Service centres of the company operate in more than 10 countries: USA, Argentina, Ecuador, Romania, Iraq, Kuwait, Indonesia, Colombia, the UAE and Egypt, Azerbaijan, Kazakhstan. In 2015 nearly 40% of the company&rsquo;s proceeds were accounted for by non-former-USSR countries.</p> <p>The results of the open competition sale procedure will be announced on August 26, 2016 at 12 midday. The main criterion in choosing the winner will be the price offered for the block of shares owned by RUSNANO. The ability of the purchaser to successfully develop the project in cooperation with other shareholders will also be taken into account.</p> Wed, 20 Jul 2016 12:00:00 +0300 NovaMedica, a RUSNANO Portfolio Company, Launches an Innovative Pharmaceuticals Technology Center <p>Russian pharmaceutical company NovaMedica (a RUSNANO portfolio company) has launched a technological center to develop and put into pilot production innovative pharmaceuticals. It includes a complex of R&amp;D laboratories and production sites with technological solutions, which are unique for the Russia pharmaceutical industry and one of the best in Europe. The key task of the Technological Center is to develop sophisticated oral pharmaceuticals of various pharmacotherapeutic groups including those to treat cardio-vascular and gastroenterological diseases, CNS diseases as well as to create new generation painkillers.</p> <p>R&amp;D laboratories of the Technological Center put into operation in late 2016 have already started working on five projects within the framework of NovaMedica&rsquo;s own R&amp;D program. Another four projects will be launched during this year. These are pharmaceuticals with innovative active agent delivery systems changing the bioavailability of drugs and allowing combining previously incompatible substances in one dose. Thanks to this, drugs that are being developed will have new application possibilities and will crucially surpass many existing analogues by their efficiency and safety.</p> <p>Investments in the establishment of the Center located in the Moscow Technopolis amounted to 945 million RUR. The Center&rsquo;s capabilities allow implementing 15-20 R&amp;D projects on its venues and producing up to 40 million pieces of products per year. Innovative products will be patented and promoted both in Russia and in international markets. NovaMedica intends to develop scientific cooperation with leading Russian and foreign pharmaceutical companies, scientific and technological centers, universities and startups.</p> <p>The development of its own portfolio of pharmaceuticals is an important but not the only task of NovaMedica&rsquo;s technological center. The company plans to maintain partnerships and implement orders to develop pharmaceuticals for foreign and national companies. The global market of pharmacological developments is 8-10 billion USD per year, the Russian market amounts to about 1 billion RUR and has been growing 15-20% per year. By 2022, NovaMedica plans to acquire about 20% of the Russian market.</p> <p>&ldquo;Today we are launching an enterprise, which may be attributed to &lsquo;big pharma&rsquo; without any exaggeration. Ultramodern equipment allowing research on a level previously unavailable in Russia, is installed here. Drugs that will be produced there are developed by largest world producers but the critical difference of NovaMedica is that we will not just produce generics, as many others do, out laboratory complex allows making our own R&amp;D. I would like to highlight the role of the Moscow authorities. It would be much more difficult without their support and the infrastructure complex created in Technopolis,&rdquo; <strong>Anatoly Chubais</strong>, Chairman of the Management Board of MC RUSNANO, said.</p> <p>&ldquo;The establishment of the Technological Center will significantly accelerate the development and release of national innovative pharmaceutical to the market. However, in order to saturate the Russian market with drugs urgently needed by Russian patients, we need to work in all areas. Today we have launched the Technological Center in Moscow and in May&mdash;within the framework of NovaMedica&rsquo;s partnership with Pfizer&mdash;we will start building an GMP plant to produce sterile injection drugs in the Kaluga region. More than 30 vital and essential pharmaceuticals to treat severe bacterial and fungal infections, inflammatory and cancer diseases will be localized at the plant,&rdquo; <strong>Leonid Melaved,</strong> a member of NovaMedica&rsquo;s Board of Directors, noted.</p> <p>&ldquo;The launch of the modern Technological Center of NovaMedica is an important step to develop the Russian R&amp;D industry, which on the one hand is an indicator of the state social and economic development and on the other hand is an interlink of import substitution in the high-tech industry of our country,&rdquo; <strong>Kirill Kaem</strong>, Vice President of the Skolkovo Fund and Managing Director of the Biomedical Technology Cluster, commented.</p> Wed, 19 Apr 2017 12:00:00 +0300 Novosibirsk Plant Liotech Expands the Sales Geography <p>New export operations and the company&rsquo;s expansion in the domestic market indicate that Liotech (Novosibirsk), company producing innovative lithium-ion batteries, is emerging from the crisis. Information about its close-down was disproved.</p> <p>At the end of January, the second consignment of trolley buses with increased operating range was shipped to Z&aacute;rate, Argentina. The distinctive feature of these vehicles produced by Trolza plant is the installed lithium-ion accumulators manufactured by Liotech. The core material of the enhanced accumulators is nanostructured lithium-iron-phosphate (LiFePO4). Such power storage devices are durable, highly stable and have a relatively low price, that is 10% lower than foreign analogues.</p> <p>In addition, as a part of Liotech and Trolza cooperation, a large consignment of trolley buses with increased operating range will be shipped in the nearest future for use in Southern Russia.</p> <p>&ldquo;At this stage, the accumulator assembly is carried out on-site; in other words, we manufacture finished products. Such provision of finished products is a new chapter in the company&rsquo;s history, which corresponds to the company&rsquo;s strategy to transfer the plant from cells production to release of finished battery banks and power storage devices. They are suitable to trolley buses with increased operating range, as well as electric buses and commercial electric vehicles,&rdquo; said <strong>Valery Yarmoshchuk</strong>, CEO, Liotech-Innovations Ltd.</p> <p>In addition, Trolza placed a new order at Liotech to develop new accumulators LFP-170 with decreased capacity and enhanced performance. The contract requires supply of 34 SKD sets of LIAB (Lithium-ion accumulator batteries with DCS and thermostating). At this moment, the documentation for this product, which is scheduled for release at the end of May, 2017, is being developed.</p> <p>Also, Liotech supplies the energy market. Thus, another RUSNANO portfolio company recently launched the hybrid electric power plant (AHEP) in the village of Menza, Trans-Baikal Territory, Russia. AHEP consists of solar modules of 120kW in total power, and two diesel generators of 200kW each. The accumulator cells for the power storage device with 300kWh capacity produced by Liotech were used for the electric power plant development. As planned, in 2017, Hevel will build two more hybrid electric power plants in the Trans-Baikal Territory, Russia, where Liotech power storage devices can also be used as a completely finished containerized product, including all electronic and control systems (the supplier&rsquo;s choice will be defined upon the tender). The latest plant&rsquo;s innovations will be used for Liotech power storage devices with a full quality assurance.</p> <p>Furthermore, Russian producers of commercial transport vehicles inquire delivery of LIAB sets both for electric motor vehicles, electric buses, and special equipment. At this moment, the finished solutions for other specialized machinery are also being developed.</p> Wed, 1 Feb 2017 12:00:00 +0300 Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences <h5>Exclusive use of Selecta&rsquo;s Synthetic Vaccine Particles (SVP&trade;) platform technology provided to Spark Therapeutics for co-administration with up to five gene therapy targets, including FVIII for hemophilia A.&nbsp;SVP may enhance gene therapies by enabling repeat dosing and mitigating other potential immune responses to an AAV capsid.</h5> <p>Spark Therapeutics (NASDAQ:ONCE) and&nbsp;Selecta Biosciences, Inc.(NASDAQ:SELB) today announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta&rsquo;s proprietary Synthetic Vaccine Particles (SVP&trade;) platform technology for co-administration with gene therapy targets, including FVIII for hemophilia A, as well as exclusive options for up to four additional undisclosed genetic targets.</p> <p>Selecta&rsquo;s immune tolerance SVP, including SVP-Rapamycin, is an investigational technology intended to suppress the formation of neutralizing antibodies to an adeno-associated virus (AAV) capsid when used in combination with gene therapies, without altering the therapeutic profile of the gene therapy. Neutralizing antibodies form in response to an initial administration of an AAV gene therapy and prevent effective subsequent usage. The potential ability to re-dose a gene therapy may be beneficial where a patient has not achieved a sufficient therapeutic expression of the transferred gene in the initial dose.</p> <p>&ldquo;Selecta&rsquo;s nanoparticle technology, which is undergoing preclinical testing in gene therapy, may prevent formation of neutralizing antibodies, and thus potentially enable re-dosing up to an optimal therapeutic profile by extending the reach of gene therapy to diseases that require higher doses or more extensive transduction of target cells than may be achieved through one-time dosing,&rdquo; said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. &ldquo;Importantly, if proven successful, the co-administration of Selecta&rsquo;s technology with a gene therapy may enable repeat dosing of AAV gene therapies in both adults and pediatric patients, potentially minimizing the risk of a T-cell immune response to the capsid.&rdquo;</p> <p>&ldquo;Gene therapy is a core area of focus for Selecta; one that we believe could benefit profoundly from our immune tolerance SVP technology platform,&rdquo; said Werner Cautreels, Ph.D., president, CEO and chairman of Selecta. &ldquo;We are excited about this license agreement with Spark Therapeutics, a recognized gene therapy leader, which accelerates the application of our SVP platform in gene therapy. Our preclinical studies in this field, together with the clinical data we have generated with SEL-212 in gout showing prevention of anti-drug antibodies, suggest that the application of our immune tolerance SVP technology to biologic therapies may greatly benefit patients with life-threatening diseases who currently lack adequate treatment options due to the occurrence of undesired immune responses.&rdquo;</p> <p>Subject to the terms of the agreement, Spark Therapeutics will make an initial&nbsp;$10 million&nbsp;cash payment to Selecta and purchase&nbsp;$5 million&nbsp;of Selecta&rsquo;s common stock. Within 12 months of the agreement&rsquo;s signing, Spark Therapeutics has agreed to pay Selecta an additional&nbsp;$5 million&nbsp;in cash and to purchase&nbsp;$10 million&nbsp;of Selecta&rsquo;s common stock. Selecta will be eligible for up to&nbsp;$430 million&nbsp;in milestone payments for each target, with up to&nbsp;$65 million&nbsp;being based on Spark Therapeutics&rsquo; achievement of specified development and regulatory milestones and up to&nbsp;$365 million&nbsp;for specified commercial milestones. In addition, Spark Therapeutics will pay Selecta tiered mid-single to low-double-digit royalties on worldwide annual net sales of any resulting commercialized gene therapy.</p> <p>The terms of this agreement do not apply to Spark Therapeutics&rsquo; ongoing investigational development programs in inherited retinal diseases (IRDs), including voretigene neparvovec for the treatment of&nbsp;RPE65-mediated IRD and&nbsp;SPK-7001&nbsp;for choroideremia. This agreement does not impact Spark Therapeutics&rsquo; ongoing Phase 1/2 trial of&nbsp;SPK-9001&nbsp;in hemophilia B in collaboration with Pfizer or its planned&nbsp;Phase 1/2 trial of&nbsp;SPK-8011&nbsp;in hemophilia A.</p> <p>Selecta independently is applying its SVP technology to its own proprietary gene therapy programs. Selecta has obtained an exclusive license from Massachusetts Eye and Ear to Anc80, an&nbsp;in silico-designed gene therapy vector, for Methylmalonic Acidemia and has options for additional pre-defined indications. Additionally, Selecta is advancing a proprietary gene therapy program for Ornithine Transcarbamylase Deficiency.</p> Tue, 6 Dec 2016 12:00:00 +0300 RUSNANO Group and the Russian Export Center to Help Enterprises of the Russian Nanoindustry to Enter Global Markets <p>RUSNANO Group and the Russian Export Center have completed a cooperation agreement. The document was signed by the Chairman of the Executive Board of Management Company RUSNANO LLC <strong>Anatoly Chubais</strong>, Chief Executive Officer of the Fund for Infrastructure and Educational Programs (FIEP) <strong>Andrey Svinarenko</strong>, and General Director of the Russian Export Center (REC) <strong>Peter Fradkov</strong>.</p> <div class="img"><img alt="RUSNANO Group and the Russian Export Center to Help Enterprises of the Russian Nanoindustry to Enter Global Markets" src="/upload/images/news/2016-05-31_REC_01_700.JPG" /> <p>From left to right: General Director of the Russian Export Center (REC) Peter Fradkov, Chairman of the Executive Board of Management Company RUSNANO LLC Anatoly Chubais, and Chief Executive Officer of the Fund for Infrastructure and Educational Programs (FIEP) Andrey Svinarenko</p></div> <p>The aim of the agreement is to provide support to Russian innovation companies as they enter foreign markets. Moreover, it is not only RUSNANO&rsquo;s portfolio companies, FIEP nanocenter residents or members of the Russian Nanoindustry Association that will be able to rely on such support but independent businesses too.</p> <p>At specialised conferences and meetings, the parties to the agreement will talk about the measures of support for the export of hi-tech products that may be provided by development institutions and public authorities of the Russian Federation. The main focus of the work undertaken by the Parties will be the promotion of Russian technology products on foreign markets.&nbsp;</p> <p>RUSNANO will compile a list of technology products competitive on the international market and oversee the interaction between its manufacturer and the Russian Export Center. The Fund of Infrastructure and Educational Programs is set to optimise the existing programs designed to stimulate demand with an understanding of the need for the promotion of nanotechnology products on foreign markets. REC will help hi-tech companies properly structure their export project and undergo all the procedures related to its registration. Furthermore, manufacturers of hi-tech products will receive assistance in the adaptation of goods for export to be in line with international standards, and will be able to participate in the support programs regarding foreign patenting as well as existing and upcoming educational projects of the Parties to the cooperation agreement.</p> <p>&ldquo;Do not limit the creation of hi-tech champions to the national market only - they need to be competitive abroad, on the world stage as well. That is why RUSNANO always sets its projects the goal of breaking out of the local market. Although the real volume of export of Russian nanotechnology products in 2015 exceeded the planned level, at 195 billion roubles compared to the planned 180 billion, I am certain that the potential is significantly greater. I believe that the signing of the agreement with REC is a vital step that will facilitate a new growth trend in the export of Russian nanotechnology products,&rdquo; noted <strong>Anatoly Chubais.</strong></p> <p>&ldquo;The development of hi-tech exports is one of the priority areas of work of the Russian Export Center, and our agreement with RUSNANO and the Fund for Infrastructure and Educational Programs will allow us to increase the support provided to exporters of hi-tech products. REC has already begun working with RUSNANO&rsquo;s portfolio companies, developing a spectrum of non-financial measures and financial support for them that involve the issues of intellectual property protection and lending funds during their export activity. I am confident that together with RUSNANO and FIEP we will be able to actively promote Russian innovations on foreign markets,&rdquo; said <strong>Peter Fradkov</strong>.</p> Tue, 31 May 2016 12:00:00 +0300 Portfolio Company of RUSNANO, NovaMedica Began Construction of a Pharmaceutical Plant in the Kaluga Region <h5>Russian pharmaceutical company NovaMedica announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the territory of &quot;Vorsino&quot; Industrial Park in the Kaluga Region.</h5> <p>The key partner of the Russian company in that project is Pfizer&mdash;one of the world&rsquo;s largest pharmaceutical companies; NovaMedica and its shareholders concluded the partnership agreement with Pfizer in December 2016. Pfizer will become the investor of plant construction and will transfer to NovaMedica the right to manufacture and commercialization of a portfolio consisting of more than 30 vital pharmaceuticals (in the form of injections), third part of which is not currently produced in Russia. The portfolio includes preparations for treatment of severe bacterial and fungal infections, cardiovascular, inflammatory and oncological diseases. The majority of them is included into the list of vital and essential drugs (VED) and some of them are also included into the Russian list of population drug coverage (PDC) and into &ldquo;7 ICD codes&rdquo; program.</p> <p>The project of the plant has been prepared by M+W Group, one of the world&rsquo;s leading companies in the market of designing of complex industrial facilities. The plant design capacity is more than 38.5 million production units (cartridges and vials) per year. The total area of production and accessory buildings and constructions will be approximately 23,000 sqm. The manufacturing lines will be equipped with production facilities of leading European manufacturers: BOSCH, Ziel, GEA-lyophyl, Bausch+Str&ouml;bel, Belimed, Seidenader, Optima, Mediseal, Uhlmann and others.</p> <p>The plant&rsquo;s manufacturing department is represented by sites producing sterile injection preparations: lyophilizates and solutions in vials and cartridges. There is also a possibility of further expansion of production of high-demand forms of injection products: pre-filled syringes, dropper bottles, disposable infusion bags. The project includes creation of isolated units for production of standard and cytostatic drugs.</p> <p>It is planned that the construction of the plant, its instrumentation and preparation for operation will be finished in 2020. The plant will meet the requirements of not only Russian but also international standards of Good Manufacturing Practice (GMP); that will allow NovaMedica to export the products to international markets in future.</p> <p>&ldquo;The pharmaceutical industry of the Kaluga Region is the most fast growing area in the regional economy. The cluster of pharmaceutics, biotechnologies and biomedicine that has been created six years ago, now includes 63 members, has the &lsquo;bronze status&rsquo; of the best European cluster practices and is one of the pilot innovative territorial clusters. The enterprises of that cluster produce more than 140 medicinal preparations and pharmaceutical substances. We attribute the further development to increased competitiveness and diversification of these products. In this regard NovaMedica&rsquo;s plans are in line with ours. It is planned to produce the pharmaceuticals on the plant that are not produced in our country. We wish the company good luck in implementation of the project. For its part, the industry is ready to render the partners all necessary assistance&rdquo;, said the Governor of the Kaluga Region <strong>Anatoly Artamonov</strong>.</p> <p>&ldquo;We are happy with the fact that the plant construction project has reached the next stage: engineering works have been finished, and the implementation of the challenging and interesting process of creation of manufacturing complex is ahead. Our common goal is putting in operation a modern plant meeting the highest standards of the global industry. We will share with NovaMedica our knowledge in the sphere of cutting-edge technologies of production of complex high quality preparations. This new plant will become a reliable supplier of pharmaceuticals essential for the public health system. It will be of real benefit for patients, doctors and Russian medical industry as a whole. I am sure that my colleagues from NovaMedica will do their best to construct the plant meeting the demands of patients&rdquo;, said the President of business unit &ldquo;Pfizer Base Therapy&rdquo; Europe and the member of the Board of Directors of NovaMedica, <strong>Petra Danielson-Wale</strong>.</p> <p>&ldquo;NovaMedica gathers pace quickly&mdash;in April 2017, the Technological Center with R&amp;D laboratories and pilot production was opened, and it is developing innovative dosage forms. A little over one month passed, and we open a new page&mdash;we commence the construction of GMP-plant in partnership with the giant of global pharmaceutical industry&mdash;Pfizer. The work on creation of that plant has been in progress literally since the moment of signing of the partnership agreement. We completed a very important stage preceding beginning of every construction&mdash;designing. Pfizer professionals from various countries having a great experience joined the project to ensure that the design of NovaMedica&rsquo;s plant is perfect in every respect. That collaboration has already provided the NovaMedica&rsquo;s team with an invaluable experience, and assured us that the project will be successfully implemented in highly effective manner&rdquo;, considers the Chairman of the Board of the Management Company RUSNANO and the chairman of the Board of Directors of NovaMedica, <strong>Anatoly Chubais</strong>.</p> <p>&ldquo;The commencement of the plant construction is an important stage of NovaMedica&rsquo;s sequential strategy of localization of innovative products and technologies in Russia. The project would be impossible without the conditions created by the state for the development of our industry. We bless the authors of &lsquo;Pharma 2020&rsquo; Programme&mdash;the Ministry of Industry and Trade, as well as the Ministry of Health and our shareholders&mdash;RUSNANO and Domain&mdash;for their consistent support, which helps to think widely, make ambitious and long-term plans and to implement them steadily. We are grateful to our shareholders for their strong intellectual contribution and all-round support that motivates NovaMedica&rsquo;s team to breakthrough development. And, of course, we are inspired by the possibility of gaining a unique experience in the process of collaboration with the leader of global pharmaceutical industry&mdash;Pfizer&rdquo;, says the Chief Executive Officer of NovaMedica, <strong>Aleksandr Kuzin</strong>.</p> Tue, 30 May 2017 12:00:00 +0300 Solar Cell Production Site Has Been Launched at the Hevel Factory, RUSNANO Portfolio Company <p>A phased launch of main systems of the modernized process line with almost doubled capacity has been started at the factory for production of solar modules by Hevel (joint venture of Renova Group and RUSNANO) in Novocheboksarsk. The site of production of photoelectric converters (PEC) constituting a solar module has been launched before other sites.</p> <p>PEC production is the main and the most complex phase of the solar module manufacturing process. The key performed operations are silicon wafer texturing, application of layers of amorphic silicon, silver or tin oxide thereon by means of magnetrons, current pickup application. The combination of these operations leads to increase of solar energy to electricity conversion ratio.</p> <p>The applied heterostructure-based technology has been developed by R&amp;D Centre of Hevel. It combines main advantages of crystal modules (high efficiency, lack of light-induced degradation) and thin-film modules (high efficiency at raised temperatures of module operation, better perception of scattered light).</p> <p>At the same time, the commissioning of the site where the cells are assembled into solar modules is coming to its end. By the end of March, the factory specialists plan to adjust all processes and proceed to solar modules production.</p> Tue, 21 Feb 2017 12:00:00 +0300 Russian Telecommunication Will Receive Domestic Optic Fibre <h5>Optic Fiber Systems, RUSNANO portfolio company, has completed certification of its products in Russia and is ready to cover up to half of the Russian market. Prior to the factory launch, the Russian needs for optic fibre have been completely satisfied due to import.</h5> <p>In December, 2016, RUSNANO portfolio company Optic Fiber Systems jointly with Rostelecom PJSC and VNIIKP OJSC (All-Russian Research and Development Institute for Cable Industry) completed a programme of testing own-produced Russian optic fibre, as well as optic fibre cable produced using it.&nbsp; Test results demonstrate positive results, and the company&rsquo;s products have been recommended to use in Rostelecom communication networks.</p> <p>Optic Fiber Systems produces optic fibre for communication cables used by telecommunication companies for data transfer. Synthetic quartz workpieces heated and pulled out to a thickness of 0.125 mm covered by protective sheath are used for production of optic fibre.</p> <p>First domestic production of telecommunication optic fibre was launched in Saransk, the capital city of Mordovia, in September 2015. The project is implemented by RUSNANO with participation of Gazprombank and the Republic of Mordovia. Total budget is 3.5 billion roubles, where RUSNANO contributed 1.7 billion roubles.</p> <p>Leading enterprises in the industry, such as Saransk Cable-Optic, Eurocable 1, Incab, Moscable-Fujikura, Opten-Cable and T8 have already tested the samples of Russian optic fibre and have given their positive feedbacks. Successful completion of certification programme with participation of Rostelecom PJSC and VNIIKP OJSC will allow to maximally expand the scope of application when building networks in Russia in the nearest future, including within the federal project &quot;Elimination of Digital Gap&quot;.</p> <p>Optic Fiber Systems have already obtained compliance certificate for commercial optic fibre according to the key international standards MSE-Т G652D and IEC 60793-2-50, and have been certified for quality management system in compliance with GOST R ISO 9001-2015 (ISO 9001: 2015) which is a warranty of compliance of domestic optic fibre quality with the international and Russian standards.</p> <p>In Q4, 2016, the factory proceeded to commercialization of optic fibre and achieved the level of over 100 thousand kilometres of fibre per month. It comprises 50% of the factory capacity and covers 25% of demand of the total Russian market, which needs have been completely satisfied due to importing prior to the factory launch.</p> <p>According to CRU Group, consumption of optic fibre in the world was increased by 11% up to 457 million kilometres in 2016. In this context, Optic Fiber Systems have successfully implemented deliveries of optic fibre in the amount of over 300 thousand kilometres to the countries of European Union and Asia, including the top ten largest manufacturers of optic fibre communication cables in China. Currently, a series of long-term export contracts have been concluded for the delivery of optic fibre.</p> <p>&ldquo;Import substitution proclaimed as one of the priorities of development of domestic industry is a primary goal in the strategically important industry as telecommunications. The results of joint tests demonstrate that Optic Fiber Systems can participate in tenders of Rostelecom itself and the other largest communication operators in Russia among the manufacturers of optic fibre cables, and the obtained compliance certificate guaranties the quality of domestic optic fibre for cable producing factories,&rdquo; has stated Deputy Chairman of the Board of RUSNANO <strong>German Pikhoya</strong>.</p> Tue, 21 Feb 2017 12:00:00 +0300 Nominations Submission for RUSNANOPRIZE 2017 Is Opened <h5>In 2017 <a href="" target="_blank">RUSNANOPRIZE</a> shall be awarded for research conducted in the fields of nanomaterials and surface modification, as decided by the Board of the <a href="/about/fiep">Fund for Infrastructure and Educational Programs</a> and due to the Regulation of the Prize nomination field choosing procedures.</h5> <blockquote>Nominations submission period will last till July 31</blockquote> <p>&ldquo;The R&amp;D in nanomaterials and surface modification field may lead to dramatic breakthroughs affecting more than one industry or sphere, such as microelectronics, metallurgy, polymers, biomedical materials, nanoscale diagnostics and many other at the same time,&rdquo; <strong>Sergey Kalyuzhny</strong>, Adviser to Chief Executive Officer&mdash;Chief Scientist of RUSNANO Group has noticed.&nbsp;</p> <p>RUSNANOPRIZE is an annual Prize awarded in one of the following fields: Optics and Nanoelectronics; Nanomaterials and Surface Modification; Medicine, Pharmacology and Biotechnologies; Energy Efficiency and Green Technologies.</p> <p>In 2013 <strong>Anatoly Chubais</strong> and Karlsruhe Institute of Nanotechnology professor <strong>Herbert Gleiter</strong> <a href="/press-centre/news/20131101-awards-ceremony-held-for-rusnanoprize-2013"><strong>presented the award for achievements</strong></a> in research conducted in the fields of nanomaterials and surface modification to <a href="" target="_top"><strong>Robert Langer</strong></a>, the David H. Koch Institute Professor at the Massachusetts Institute of Technology, and <a href="" target="_blank"><strong>Omid Farokhzad</strong></a>, associate professor at Harvard Medical School and physician-scientist in the Department of Anesthesiology at Brigham and Women&rsquo;s Hospital. They were awarded the prize for developing nanoparticle technologies for medical applications.</p> <p>The Prize is awarded annually to researchers, scientists and developers (up to three people) being the authors of scientific-technological discovery or discoveries in the field of nanotechnologies, and to the company being the first to apply the discovery (discoveries) to mass production with the annual production output of at least $10 million and reached business success through the application of the discovery (discoveries). Financial rewards, prize symbols and honorary diploma of the Prize are awarded to inventors, scientists and developers, the authors of the R&amp;D projects or technologies implemented into production. The company that has achieved some significant commercial success due to the implementation of these technologies is awarded with an honorary diploma and a glass ball, which is a RUSNANOPRIZE symbol.</p> <p>Both Russian and foreign organizations as well as personalities, save for <strong><a href="" target="_blank">Prize Awarding Committee</a></strong> members, can nominate a researcher (researchers) for the Prize, self-nomination is also possible.</p> <h5>Applications are accepted and registered by the Prize Directorate at&nbsp;<a href=""></a> in strict compliance with the <a href="" target="_blank">Nomination Form</a>. For more details and application form, please visit <a href="" target="_blank"></a></h5> Tue, 2 May 2017 12:00:00 +0300 Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers <p>Selecta Biosciences, Inc.&nbsp;(NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has licensed LMB-100, a next-generation immunotoxin, from the&nbsp;Center for Cancer Research&nbsp;(CCR) at the NCI, part of the&nbsp;National Institutes of Health. LMB-100 contains a potent bacterial toxin that binds to mesothelin, a protein expressed in all mesotheliomas, pancreatic adenocarcinomas and a high percentage of other malignancies, including lung, breast and ovarian cancers.</p> <p>&ldquo;This marks yet another major milestone for&nbsp;Selecta&nbsp;as we execute on our strategy to enable a range of proprietary, non-immunogenic biologic therapies using our proprietary immune tolerance platform,&rdquo; said&nbsp;<strong>Werner Cautreels</strong>, Ph.D., President, CEO and Chairman of&nbsp;Selecta. &ldquo;By in-licensing this promising clinical-stage product candidate, we are extending our footprint to include oncology, where the efficacy of many biologic treatments is hampered by immunogenicity. Based on our preclinical work with NCI, we believe a combination treatment of LMB-100 and our proprietary SVP-Rapamycin may allow patients with rare, serious and aggressive forms of cancer to tolerate and benefit from multiple immunotoxin treatment cycles.&rdquo;</p> <p>CCR is in the process of completing two clinical trials of LMB-100 in patients with mesothelioma and pancreatic cancer that are intended, in part, to help define the maximum tolerated dose. For more information about these trials, call 1-800-4-Cancer (1-800-422-6237) (TTY:&nbsp; 1-800-332-8615) and/or visit&nbsp;<a href="" target="_blank"></a>. Initial data indicate that undesired antibody responses to the immunotoxin prevented most patients from receiving the intended four treatment cycles. While a precursor to LMB-100 was similarly restricted by immunogenicity despite the concurrent use of potent immunosuppressive drugs, tumor regression was observed in the only two patients who were able to receive more than two cycles of treatment. These results suggest that the mitigation of immunogenicity may enable more patients to benefit from LMB-100 therapy.</p> <p>In 2016, preclinical research under a&nbsp;Cooperative Research&nbsp;and Development Agreement between&nbsp;Selecta&nbsp;and NCI demonstrated that the co-administration of SVP-Rapamycin and LMB-100 has the potential to enable extended treatment with LMB-100 and, therefore, enhance its anti-tumor activity. Selecta&rsquo;s immune tolerance Synthetic Vaccine Particles (SVP&trade;) prevented the formation of anti-LMB-100 antibodies, allowing for the administration of repeat treatment cycles in mouse models and enabling the full beneficial effect of LMB-100 on tumors in a tumor model.&nbsp;Selecta&nbsp;and NCI are currently in discussions regarding a planned Phase 1b clinical trial to evaluate multiple cycles of this combination treatment.</p> <p>Under the terms of the license agreement, NCI will receive an upfront payment of&nbsp;$50,000&nbsp;from&nbsp;Selecta. NCI also is entitled to up to&nbsp;$9.25 million&nbsp;in payments for milestones and low single-digit royalties on worldwide annual net sales of any resulting commercialized treatment.</p> Tue, 2 May 2017 12:00:00 +0300 RUSNANO Begins to Search a Buyer of Its Share in Its Portfolio Company Eterno <h5>RUSNANO achieved all goals of the project. It created a world-class plant manufacturing products&mdash;stamp-welded parts for pipelines&mdash;that substituted western suppliers at the market. The minimum price of PUSNANO&rsquo;s block (49.89%) is RUR&nbsp;4.72&nbsp;bln. The buyer will be searched for through an open bidding procedure.</h5> <p>ETERNO is a new project of white metallurgy, which produces couplings for pipelines using nanostructured materials. The plant was built under a joint project run by RUSNANO and the Chelyabinsk Pipe-Rolling Plant. The adoption of nanotechnologies allowed to achieve a sufficient increase in durability and service reliability of products. One of the technologies is seam welding using titanium and boron whose nanosized junctions contribute significantly to the hardened structure of the goods.</p> <p>ETERNO plans to produce up to 150&nbsp;new products per year for strategic projects, such as the second run of the products pipeline</p> <p>&ldquo;Novy Urengoy&mdash;Surgut&rdquo;, gas pipe line &ldquo;Nord Stream&nbsp;2&rdquo;, projects on meeting maintenance demands of Gazprom, Rosneft and oil and gas companies of CIS countries.</p> <p>&ldquo;It can be said with confidence that we not merely built a new unique plant, but using nanotechnology and modern approaches to production made a contribution to creation of a new branch of industry&mdash;white metallurgy&rdquo;, noted the deputy Chairman of the Board of the Management Company RUSNANO, <strong>Oleg Kiselyov</strong>.</p> <p>We expect that the results of the preliminary qualification will be summed up by July&nbsp;07, 2017. The main criterion in choosing the winner will be the price offered for the block of shares owned by RUSNANO. The ability of the purchaser to successfully develop the project in cooperation with other shareholders will also be taken into account.</p> <p>The conditions for filing of application are available at <a href="" target="_blank"></a></p> Tue, 13 Jun 2017 12:00:00 +0300 Quantenna Wins the Prestigious Global Semiconductor Alliance Award for the “Most Respected Private Semiconductor Company” a Second Consecutive Year <p>Quantenna Communications, Inc. (NASDAQ:QTNA), a leading provider of high-performance Wi-Fi solutions, announced today that it received the prestigious &ldquo;Most Respected Private Semiconductor Company&rdquo; award at the 2016 Global Semiconductor Alliance (GSA) Awards Dinner Celebration on December 8th, 2016. The semiconductor industry&rsquo;s annual event honored outstanding semiconductor companies worldwide that have demonstrated excellence through their vision, strategy, execution and future opportunity.</p> <p>The GSA identified leading semiconductor companies that have demonstrated market growth through technological innovation and exceptional business management strategies. The awards are voted by GSA&rsquo;s member companies to honor their achievements. Previously, Quantenna won the &ldquo;Start-Up to Watch&rdquo; award in 2013 and last year earned the &ldquo;Most Respected Private Company&rdquo; award. Quantenna recently completed its initial public offering and is now listed on NASDAQ; the award vote was cast prior to its IPO.</p> <p>&ldquo;GSA has been following Quantenna&rsquo;s growth for many years and recognized the company with three awards in two different categories in the last four years,&rdquo; said <strong>Jodi Shelton</strong>, President of GSA. &ldquo;GSA also congratulates Quantenna on their recent IPO and looks forward to their continued success.&rdquo;</p> <p>&ldquo;We are humbled that the GSA and our peers have again recognized Quantenna as a company that is relentlessly pushing the semiconductor Wi-Fi market,&rdquo; said <strong>Dr. Sam Heidari</strong>, Chairman and CEO at Quantenna. &ldquo;This award is the perfect ending to our journey as a private company and we look forward to writing a new chapter of our success as a public company.&rdquo;</p> Tue, 13 Dec 2016 12:00:00 +0300 RUSNANO Sells its Interest in Uralplastic-N to Strategic Investor Mondi Group <p>RUSNANO announces sale of its interest in the portfolio company Uralplastic-N&mdash;one of the leaders of the Russian polymer packaging market. RUSNANO is selling its interest to the project&#39;s strategic investor, international packaging and paper group&mdash;Mondi.</p> <p>RUSNANO joined the project in 2010. The inflow of investments allowed one of the largest Russian full-cycle plants manufacturing flexible polymer packaging to be built from the ground up in a short timeframe. Three new process technologies were implemented at the plant: the production of nanocomposites, their introduction into the composition of the film and the production of film modified with nanocomposites.</p> <p>The use of nanocomposites allows it to be recycled, reduces the number of packing layers, its thickness and weight, and considerably increases its barrier characteristics.</p> <p>The plant&rsquo;s capacity is about 1,200 tons of flexible packaging per month, which is equal to approximately 500 million pieces of packaging for finished products.</p> <p>Over the past two years, the company&#39;s revenue increased significantly and reached about 2 billion rubles in 2015. In Q1 2016 the company exceeded the target for revenue by 5% and EBITDA by 10%.</p> <p>The production facility located in the town of Aramil, Sverdlovsk Region, is fitted with unique equipment for the production of nanocomposites&mdash;the only 10-layer extrusion line in Russia for the manufacturing of highly hermetic film and an unparalleled raw material batching system. These films allow the increase of the shelf life of products without the use of preservatives. The product portfolio of the company includes a wide range of packaging for the food industry (various types of flexible packaging for dairy products, meat, fish, seafood, spices and sauces), for household and personal care products, cement and dry construction mixtures and other industrial materials.</p> <p>In the process of manufacturing its products Uralplastik-N relied on the development and increase in the use of domestic raw materials. An analysis and testing of raw materials, produced by Russian manufacturers, were conducted by the company&rsquo;s own R&amp;D-centre. Following the results of research, one changed the composition of the films produced, which allowed the replacement of imported components in a number of products by similar domestic ones without loss of quality. In 2015, the share of domestic raw materials increased to 44% as compared to 29% in 2014.</p> <p>&ldquo;The acquisition of Uralplastic supports the development of our Consumer Packaging business and strengthens our presence in the Russian consumer packaging market, complementing our existing plant in Pereslavl, near Moscow and allowing us to improve our offering to customers in this growing market,&rdquo; said <strong>David Hathorn, Chief executive of Mondi Group</strong>.</p> <p>&ldquo;I&rsquo;m proud of what we&rsquo;ve achieved with Uralplastic. It has grown significantly over the years and it now joins a reputable international company that will ensure the future success of the business,&rdquo; said <strong>Alexey Goncharov, co-owner of Uralplastic-N.</strong></p> <p>&ldquo;A world class plant has been built within the six years of our participation in the project. This is a pure &lsquo;greenfield&rsquo; project. The implementation of nanotechnologies, which constitute the core of the company&rsquo;s products, has allowed the company to become a market leader,&rdquo; said<strong> Dmitry Lisenkov,</strong> <strong>Managing Director, RUSNANO Management Company</strong>.</p> Tue, 12 Jul 2016 12:00:00 +0300 Russian Technologies Will Aid Indonesia in Space Exploration -indonesia-in-space-exploration <p>On October 31 the 11th session of the Russian-Indonesian Joint Commission on Trade, Economic and Technical Cooperation took place where RUSNANO that invests in the production based on the state-of-the-art developments in the field of nanotechnologies and the Indonesian infrastructure company with state support PT Wijaya Infrastruktur Indonesia signed an agreement on the establishment of the International Aerospace Equity Fund (IASF). The agreement was signed in the presence of the Minister of Industry and Trade of the Russian Federation <strong>Denis Manturov</strong> and Coordinating Minister for Economic Affairs of the Republic of Indonesia <strong>Darmin Nasution</strong>. On the Russian side it was signed by Managing Director for the Investment Activity of RUSNANO Management Company <strong>Dmitry Pimkin</strong>, on the Indonesian side&mdash;by President, CEO of PT Wijaya Infrastruktur Indonesia <strong>Didi Suwondo</strong>.</p> <p>Indonesia became the first foreign participant of RUSNANO Aerospace Fund. The initial size of the joint investment will amount to $100 million, which will be invested over 5 years in the development of navigation systems and satellite communication systems, in the production of new materials and components for satellites, in the development and manufacture of aircrafts and other related sectors of economy. The investment period can be extended for two years, and the operation period of the new fund is 10 years with possibility of extension for another three years.</p> <p>Expansion of IASF participants list is planned in the future by means of accession of other countries in the Asia-Pacific region that are interested in the creation of their pace infrastructure for telecommunications and monitoring of Earth&rsquo;s surface. RUSNANO plans to raise the level of the fund up to $500 million.</p> <p>According to the Managing Director for Investment Activity of RUSNANO Management Company, <strong>Dmitry Pimkin</strong>, &ldquo;rapidly growing economies of the Asia-Pacific countries&mdash;such as Indonesia&mdash;attract RUSNANO&rsquo;s close attention to this region. This attention is mutual: latest Russian technologies and developments &nbsp;recurrently prove their competitiveness in the world market. Moreover, aerospace expertise of Russia and Russian companies is beyond any doubt. The newly created Aerospace Fund will be one of the tools for Russia to promote domestic high-tech production in the world market, and for the partner countries it provides an opportunity to implement national commercial space programs.&rdquo;</p> <p>One of the first investment projects of the Fund will be the creation of its own satellite constellation that would form the basis of a system of prompt detection of fires and gas explosions. In general, IASF portfolio will be formed by projects that will solve a variety of tasks&mdash;from development and production of control systems for spacecraft to production of geosynchronous satellite systems and all the necessary ground infrastructure for the development of telecommunication network of the whole country.</p> <p>Russia, being one of the world leaders in the aerospace industry, has extensive experience in the development of outer space. The country has both experience in creation of advanced aerospace infrastructure and the latest developments in this field. RUSNANO is one of the key development institutions financing the introduction of new technologies in the Russian production.</p> Tue, 1 Nov 2016 12:00:00 +0300 White Metallurgy Company ETERNO Has Launched Production of Import-substituting Products Unique to the Russian Market. The Ceremony Was Attended by the President of the Russian Federation Vladimir Putin <p>Today, Chelyabinsk factory ETERNO founded by JSC Chelyabinsk Pipe-Rolling Plant (ChelPipe) and RUSNANO held a ceremony to mark the launch of production of stamp-welded parts (split tees) with the use of nanotechnology. The President of the Russian Federation <strong>Vladimir Putin</strong>, the Minister of Industry and Trade of the Russian Federation <strong>Denis Manturov</strong>, the Chairman of the Board of RUSNANO <strong>Anatoly Chubais</strong>, the Plenipotentiary Representative of the President of the Russian Federation in the Ural Federal District <strong>Igor Kholmanskikh</strong>, the Governor of the Chelyabinsk Region <strong>Boris Dubrovsky</strong>, and ChelPipe Group shareholders <strong>Andrey Komarov</strong> and <strong>Alexander Fedorov</strong> officially launched the production of the new import-substituting products.</p> <p style="text-align: center;"><img alt="" src="" /></p> <p>ETERNO&rsquo;s split tees will allow for conducting repairs of the main pipelines under a working pressure of up to 9.8 MPa and then putting them into operation without stopping the flow of hydrocarbons. Thus far, it has been foreign manufacturers that have carried out the supply and tying-in of split tees without interrupting flow for Russian energy companies. ETERNO is planning to produce up to 150 units of new products on an annual basis as part of its strategic projects. This includes the second line of the Novy Urengoy&mdash;Surgut product pipeline, the Nord Stream 2 pipeline, as well as the projects that meet the repair and maintenance needs of Gazprom, Rosneft, and other oil and gas companies in the CIS. Launch of ETERNO&rsquo;s new product range is a step towards almost entirely achieving full import substitution in pipeline production.&nbsp;</p> <p>&ldquo;We are in the process of becoming not only independent in terms of imports, but nanotechnology allows us to produce more reliable and more stable world-class level products. In collaboration with our partners, we are creating White Metallurgy&mdash;an area that fundamentally changes the perception of the industry as conservative and dirty. We are confident that our investment of over 4.5 billion roubles is of strategic importance,&rdquo; said Chairman of the Board of MC RUSNANO <strong>Anatoly Chubais</strong>.</p> <p>&ldquo;The domestic market for split tees is rapidly growing, and we are prepared to offer our customers a number of obvious competitive advantages: efficient execution of orders, an individual approach, and high quality products made with modern materials, technologies and equipment. The launch of split tee production sees ChelPipe Group taking its latest important step in developing integrated supply, guaranteeing that the consumer enjoys uniform high quality standards for each and every item on the product range: pipes, couplings and other pipeline components,&rdquo; said ChelPipe Group shareholder <strong>Andrey Komarov</strong>.</p> <p>The ceremony was also attended by graduates of the corporate educational program led by the ChelPipe Group&mdash;the Future of White Metallurgy. The young mechatronics specialists created a program that allowed for launching the machines and assembly units involved in the technical process of producing split tees automatically especially for the ceremony.</p> <p style="text-align: center;"><img alt="" src="" /></p> <p>After the official ceremony marking the launch of production, Vladimir Putin visited the exhibition of RUSNANO&rsquo;s nanotechnology projects in new industrial sectors, which was hosted at ETERNO&rsquo;s premises.</p> <p>During the visit, the President also held an informal meeting with the staff and long-standing employees of the ChelPipe Group&rsquo;s enterprises.</p> Thu, 8 Dec 2016 12:00:00 +0300 RUSNANO Demonstrates IFRS Profit for the Third Consecutive Year <h5>RUSNANO Group, consisting of RUSNANO and consolidated subsidiaries (including MC RUSNANO LLC), announces financial performance indicators based on 2016 results in accordance with the International Financial Reporting Standards (IFRS).</h5> <p>In 2016, RUSNANO Group received a profit of 4.5 billion RUR.</p> <p>The net income from RUSNANO financial assets by fair value amounted to 5.6 billion RUR in 2016.</p> <p>The fair value of the investment portfolio was 140.6 billion RUR in 2016 compared to 140.4 billion RUR in 2015. At the historical cost assessment, a growth in the value of assets denominated in every currency amounted to 11.4 billion RUR, 11.3 million USD, and 1 million EUR respectively. In general, the investment portfolio profit without taking into account exchange rate differences was about 12.3 billion RUR.</p> <p>In 2016, revenues from exits from investment projects equalled 17.8 billion RUR, which is more than 2.6 times more than the same indicator of 2015 (6.8 billion RUR). The largest and most successful exits include the sale of RUSNANO shares in such companies as Micron, Danaflex-Nano, DSK Grad, Uralplastic, and Nikomag. The average yield (IRR) of 11 exits sold in 2016 calculated to the value of the portfolio at the time of transfer of assets under the management of MC RUSNANO was about 11%. The average IRR for all exits for all the time is 14.9%.</p> <p>In 2016, the fair value of the portfolio taking into account revenues from exits exceeded investments by 1.7 billion RUR.</p> <p>The RUSNANO debt in 2016 was reduced by 16.4 billion RUR including early repayment of obligations for 2.6 billion RUR. In 2016, interest payments amounted to 15.8 billion RUR compared to 13.2 billion RUR paid in 2015. In general, for the entire period of its activity, RUSNANO allocated 63.7 billion RUR to service the debt as interest and coupon payments and more than 41 billion RUR to repay the principal.</p> <p>As a result of 2016, the total amount of funds attracted from third-party investors in 4 new funds amounted to 20 billion RUR. In addition, in early 2017 the creation of two more new funds was approved, thanks to which attracted investments will equal 48 billion RUR. In accordance with RUSNANO&rsquo;s long term development strategy, the amount of funds attracted to new funds will be 150 billion RUR in 2020.</p> <p><strong>Boris Podolsky</strong>, Deputy Chairman of the Management Board&mdash;Managing Director of MC RUSNANO, said, &ldquo;RUSNANO reporting clearly demonstrates the process we have been talked about: the first investment cycle is coming to an end; we are exiting portfolio companies and are starting the second investment cycle. By 2017, we have exited 27 projects and in the upcoming years this trend will increase. Most exits from RUSNANO projects are planned for 2017-2019.&rdquo;</p> Thu, 27 Apr 2017 12:00:00 +0300 RUSNANO and Fortum Create a Wind Energy Development Fund <h5>The Boards of Directors of RUSNANO and Finnish company Fortum approved the establishment of an investment wind energy development fund, with a view to invest in the construction of wind parks and launch projects on the wind turbine production localization as well as venture projects in renewable energy.</h5> <p>The parties are considering the possibility to construct and put into operation wind parks with a total capacity of several hundred Megawatts within 5 years, which will allow taking a significant share of the Russian wind energy market.</p> <p>Within the partnership, RUSNANO and Fortum on a parity basis intend to invest a total of 30 billion RUR in these projects. The financing of projects will also be carried out through obtaining Russian project financing (without recourse to borrowers). The interest in participating in the project has been voiced by a number of largest banks.</p> <p>A foreign supplier of wind turbines from among the world&#39;s largest producers, with whom RUSNANO and Fortum are at the final stage of negotiations, will be selected to implement the project. One of the main conditions of the selection of the supplier is the equipment production localization program on the Russian territory. The localization level will increase annually and should reach 65% by 2019.</p> <p>In addition to the participation in the Fund RUSNANO intends to independently invest in localization projects up to 1 billion RUR. Such projects are planned to be implemented together with the selected supplier and its OEM partners as well as Russian technological partners. The investments will be aimed at creating the production of nodes and components of wind turbines: blades, towers, generators and other components. The listed products will be, among other things, manufactured using nanotechnologies. The Project implementation will give effect in related industries (metallurgy, materials science, power engineering, construction, engineering, service), allow including Russian enterprises in the global supplier chain and realizing their export potential.</p> <p>In 2017, Fortum plans to complete the construction of a wind park with a capacity of 35 MW, which is supposed to be included in the partnership. The selection of sites for other wind parks with potential investments from the fund, is being made in Rostov, Ulyanovsk, Murmansk, Krasnodar and Stavropol regions, the Republic of Tatarstan and other regions. Promising development areas are determined based on wind parameters, logistics, accessibility of the power grid infrastructure and readiness of the local authorities to support the implementation of projects.</p> <p>The global wind energy market continues to develop in a sustained way: more than a half of global wind power generation was launched for the last 5 years. Wind was a key source of new generation in Europe and the USA, and the second in importance in China. The total capacity of all wind parks put into operation in the world as of now amounts to about 500 GW.</p> <p>Thanks to its geographical and climatic features, the Russian Federation has the largest wind power potential in the world. The creation of the Fund and the launch of localization projects will allow forming two new high-tech industries in Russia: production of equipment for wind generation and construction and operation of wind parks.</p> <p>It is planned that within 3-5 years wind parks constructed and put into operation may interest financial strategic partners as well as energy companies investing in renewable generation.</p> Thu, 27 Apr 2017 12:00:00 +0300 First Solar Diesel Electric Power Plant in the Trans-Baikal Territory Is Launched <p>On January 26, 2017, PJSC &ldquo;Rosseti&rdquo; in cooperation with Hevel Group of companies launched the first autonomous hybrid electric plant (AHEP) in the village of Menza, Trans-Baikal Territory, Russia, to provide uninterruptible power supply to three hard-to-reach villages.</p> <p>AHEP consists of solar modules of 120kW in total, two diesel generators of 200kW each, and a power storage device of 300kWh capacity.</p> <p>Use of solar modules and a modern intelligent control system of the electric plant will allow decreasing the consumption of diesel fuel from 250,000 to 86,000 litres per year. AHEP will decrease the atmospheric emissions of carbon dioxide by 500 tons within a year.</p> <p>The implementation of the project within the frameworks of public-private partnership has allowed to avoid the growth of the tariff burden on end consumers of the electric power, and guarantees the reduction of expenses from the regional budget due to the reduction of subsidies to compensate for the costs of the diesel fuel delivery. The project provider from the part of PJSC &ldquo;Rosseti&rdquo; was its subsidiary PJSC &ldquo;IDGC of Siberia&rdquo;.</p> <p><strong>Natalya Zhdanova</strong>, Head of the region, emphasized that the launch of the first solar diesel electric power plant in the Trans-Baikal Territory is an example of successful private-public partnership.</p> <p>&ldquo;Without any exaggeration, we are participants and witnesses of a significant event both for our region and our country in general. It is the first solar energy power plant in the Trans-Baikal Territory. At the same time, it is a good example of successful private-public partnership, an example of the fact that the authorities and businesses can jointly solve specific real-world problems.</p> <p>We have a lot of sun in the Trans-Baikal Territory. In addition, we have a lot of remote and hard-to-reach areas. Today, 23 residential localities of our region need stable and quality energy supply. Our task is to fully solve the problem of energy supply to these localities in the next three years. It is already planned to build two additional solar electric power plants in the region in 2017 in order to improve the quality of life of residents of the remote areas and provide their economic development.&rdquo;</p> <p>As <strong>Roman Berdnikov</strong>, First Deputy General Director, PJSC &ldquo;Rosseti&rdquo;, said: &ldquo;Rosseti is fulfilling a complex programme to modernize the network service complex in the Trans-Baikal Territory. I&rsquo;m sure that our experience of collaboration with the Trans-Baikal Territory will become a positive example for other Russian regions that are now looking for the solutions of the top-priority government task - to improve the reliability and quality of the power supply in the remote and isolated territories.&rdquo;</p> <p><strong>Igor Shakhray</strong>, General Director of Hevel Group of companies, noted: &ldquo;I&rsquo;m glad that we managed to jointly find such formula for the project fulfilment that helps improve the quality of life of residents in the remote and isolated areas and make this project cost-effective with no increase of expenses from the budget. The first return on investment will be completed within the frameworks of the energy-service contract and will be tied to reduction of expenditures for diesel fuel; therefore, we are, as investors, directly interested in the electric power plant efficiency increase.&rdquo;</p> <p>The autonomous hybrid electric power plant in the village of Menza is also a pilot project being a part of implementation of the National energy-sector project Development of Local and Integrated in the UES Sources of Energy Supply based on Photoelectric Heterostructure New Generation Modules.</p> <p>The programme of construction of over 100 autonomous hybrid electric power plants (AHEP) until 2021 was developed within the National project.</p> <p>The ceremonial launch of the first power plant was attended by: Aleksey Teksler, First Deputy Minister of Energy of the Russian Federation; Natalya Zhdanova, Governor of the Trans-Baikal Territory; Igor Shakhray, General Director, Hevel Group of companies; Viktor Pazdnikov, Minister of Territorial Development of the Trans-Baikal Territory; and Vitaly Ivanov, Acting General Director, PJSC &ldquo;IDGC of Siberia&rdquo;.</p> Thu, 26 Jan 2017 12:00:00 +0300 RUSNANO's Portfolio Company Profotech and Maxwell Technologies SA (Maxwell) Have Signed an Agreement on Cooperation in the Field of Manufacturing and Marketing of Combined Optoelectronic Current and Voltage Transformers <p>France held the international exhibition CIGRE 2016, where RUSNANO&rsquo;s portfolio company Profotech and Maxwell Technologies SA (Switzerland) signed the Heads of Agreements on cooperation in the field of manufacturing and marketing of combined optoelectronic current and voltage transformers.</p> <p>The agreement sets out the principles of co-production, international certification and implementation of projects with the use of combined optoelectronic current and voltage transformers in Russia and internationally. This product, created by joint efforts of engineers and scientists of both companies, is a key element of building intelligent networks and digital substations and serves as a single source of data for all secondary smart devices.</p> Thu, 25 Aug 2016 12:00:00 +0300 RUSNANO’s Portfolio Company Profotech and Maxwell Technologies SA (Maxwell) Gave an International Presentation of their New Joint Product: Combined Optic-Electronic Current and Voltage Transformers <p>Profotech and Maxwell Technologies SA (Maxwell) gave a &lsquo;live&rsquo; presentation of their new joint product&mdash;combined optic-electronic current and voltage transformers (123 kV) at the 16th International Exhibition and Conference on Electric Power Equipment and Technology, EP China/Electrical China 2016, held in Beijing. Representatives of design, electric power, generation and engineering companies from China, India and Europe were invited to attend and discuss the product and solutions based on it.</p> <p style="text-align: center;"><iframe allowfullscreen="" frameborder="0" height="394" src="" width="700"></iframe></p> <p>Combined optic-electronic current and voltage transformers are a unique technology with no equivalent worldwide. They combine all the advantages of two electronic transformers in one. Their reduced size and weight compared to conventional electromagnetic transformers means that combined transformers can be installed even &nbsp;in small substations where there is limited space.</p> <p>This product is key in building smart networks, digital substations and serves as a single data source for all secondary smart devices.</p> <p>The product is the result of joint development work undertaken by engineers and scientists from both Profotech and Maxwell. Currently, the companies produce transformers able to handle 123 kV, but are planning to release higher voltage versions in the future.</p> <p>Maxwell will promote the new product on the international market.</p> <p>&ldquo;There is no doubt that our companies&rsquo; product will make a splash on the market of intellectual devices for smart grid networks in the near future. We can see great commercial potential for our new product. It is now even smaller, smarter, and, judging by the interest shown by Chinese and Indian energy companies at the exhibition, will undoubtedly be in demand in the near future! Profotech has already begun to expand its manufacturing output in light of the growing demand for its product,&rdquo; said <strong>Oleg Rudakov</strong>, General Director of Profotech.</p> Thu, 17 Nov 2016 12:00:00 +0300 Hevel Group to Increase Solar Generation in the Altai Republic up to 95 MW <p>Hevel Group (a joint venture between Renova Group and JSC RUSNANO) is to increase the amount of solar generation projects in the Republic of Altai. The corresponding arrangement was fixed in the agreement between the Government of the Republic of Altai and Hevel, which was signed at the St. Petersburg International Economic Forum.</p> <p>Let us recall that Hevel put two solar power plants each with a capacity of 5 MW <a href="/press-centre/news/20151222-the-second-stage-of-the-Kosh-Agach-solar-power-plant-brought-on-line-in-the-Republic-of-Altai">into operation in the Kosh-Agachsky district</a> of the Altai Republic in 2014 and 2015. These stations already supply electricity to the grid. At present, the construction of a third solar power plant in the region with a capacity of 5 MW, the Ust-Kan SPP, is being finalized.</p> <p>The signed agreement provides for the construction of five solar power facilities with a total installed capacity of 80 MW in Ongudaisky, Maiminsky and Ust-Koksinsky districts of the Altai Republic by 2020. The total volume of investment in the project amounts to over 12 billion roubles.</p> Thu, 16 Jun 2016 12:00:00 +0300 Anatoly Chubais Took Part in Panel Session The Big Challenges in Promoting Scientific Development at SPIEF 2016 <p>Chairman of the Executive Board of RUSNANO Management Company <strong>Anatoly Chubais</strong> spoke at the panel session The Big Challenges in Promoting Scientific Development that took place as part of the business program of the annual St. Petersburg International Economic Forum (SPIEF).</p> <p><iframe class="imgur-album" frameborder="0" height="560" src=";text=1a1a1a&amp;link=4e76c9" width="700"></iframe></p> <p>During his speech, Anatoly Chubais described the various stages of venture project financing and shared his experience related to the difficulties in relations between the investor and the financed company. He also noted the importance of the development of the innovative economy in Russia.</p> <p>Chairman of the Executive Board of MC RUSNANO <strong>Anatoly Chubais</strong>: &ldquo;Due to the fact that we built up the market economy itself from scratch, it has been vital to create an innovative economy in Russia as well. Yet it cannot be built on Soviet principles, if the whole economy in essence is a market economy. In this sense, we are lagging behind a little, but since 2005-2006, we have started to create this very innovative economy, without which there would be no demand for science. Much has been done and, despite continuous criticism, we can see the results of these efforts. However, the most important element is still lacking&mdash;the real interest of private business in the development of an innovative economy. We have already covered half the ground, and if we manage to cover the rest, we will have a real, well-founded, external demand for science.&rdquo;</p> <p>The panelists were: President of the Russian Academy of Sciences <strong>Vladimir Fortov</strong>, President of Skoltech <strong>Alexander Kuleshov</strong>, Chairman of the Scientific publishing house <strong>Elsevier B.V. Yonsuk Chi</strong>, Chairman of the Scientific Coordination Council of FASO Russia <strong>Yuri Balega</strong>, Professor of the University of Wisconsin-Madison (USA) <strong>Steven Durlauf</strong>, Vice President and General Manager in Central and Eastern Europe, IBM Corporation <strong>Michel Charouk</strong>, President of the Kurchatov Institute <strong>Mikhail Kovalchuk</strong>. The moderator of the session was Aide to the President of the Russian Federation <strong>Andrei Fursenko</strong>.</p> Thu, 16 Jun 2016 12:00:00 +0300 Telefonica Selects Quantenna Wi-Fi Client Solutions for Their Future Line of Wireless Set-Top Boxes <h5>Telefonica Will Integrate Quantenna&rsquo;s Wi-Fi Solutions for Their New Range of Wireless IP, Cable and Satellite Set-Top Boxes to Be Deployed Worldwide</h5> <p>Quantenna Communications, Inc., a leader in ultra-high performance Wi-Fi, announced today that&nbsp;Telefonica&nbsp;selected Quantenna&rsquo;s new QSR2000C product line to power all of Telefonica&rsquo;s new generations of wireless set-top boxes.</p> <p>Telefonica&rsquo;s new range of 4K ultra HD and HD wireless set-top boxes addresses all video service requirements and deployment topologies required by the various countries Telefonica operates in around the world: DTH, CATV, IPTV. Depending on the video service and countries, wireless set-top boxes will be powered by Quantenna&rsquo;s 4x4, 2x4 or 2x2 solutions.</p> <p>&ldquo;Telefonica has been deploying Quantenna&rsquo;s previous Wi-Fi solutions in their residential gateways, video bridges and set-top boxes,&rdquo; said <strong>Lionel Bonnot</strong>, Senior Vice President of Marketing and Business Development at Quantenna. &ldquo;We are honored that Telefonica renewed their trust in our solutions for their future generation of market leading wireless set box-boxes. We are particularly excited about the wide scope of the engagement and the breadth of technologies and geographical coverage it involves.&rdquo;</p> <p>From Telefonica&rsquo;s point of view, choosing a Wi-Fi supplier has become a strategic decision for the evolution of TV services. Wi-Fi performance is a key enabler for Telefonica to simplify the customer premises installation and to provide the higher quality of experience expected by Telefonica customers.</p> Thu, 15 Sep 2016 12:00:00 +0300 The Fund Created by RUSNANO and Fortum Won the Tender for Construction of Wind Parks <p>The bids of the investment Fund of Wind Power Engineering Development that has been created by RUSNANO and Fortum for 1,000&nbsp;mW have been selected within the tender of investment projects of construction of power generating plants on the basis of renewable energy sources.</p> <p>The selected bids were submitted in respect of the projects that should be put into operation in 2018-2022. The projects will be implemented under the contracts for provision of power&nbsp;(CPP) concluded for the term of 15&nbsp;years.</p> <p>Within the partnership, RUSNANO and Fortum on a parity basis intend to invest RUR&nbsp;30&nbsp;bln into construction of the wind parks in Russia. For the purpose of implementation of the projects it is planned to attract a debt financing of the projects.</p> <p>The investment decisions will be made for every individual project under the general mandate of the Fund of Wind Power Engineering Development.</p> <p>&ldquo;We are satisfied with the results of the tender. The winning makes the portfolio company of our fund&mdash;Fortum Energia&mdash;the largest player of the Russian alternative energetics in general and of wind-power engineering sector in particular. We are going to implement one of the most ambitious projects in the existing domestic renewable power generation sector, and we are sure that we will meet that challenge&rdquo; noted the deputy head of the Investment Division&mdash;head of the Perspective Energy Projects Unit of the MC RUSNANO, <strong>Alisher Kalanov</strong>.</p> <p>In addition to the investments within the Fund, RUSNANO intends to invest additionally up to RUR&nbsp;1&nbsp;bln into equipment localization projects. The investments will be aimed at creating the production of nodes and components of wind turbines: blades, towers, generators and other components.</p> Thu, 15 Jun 2017 12:00:00 +0300 RUSNANO Successfully Quitted DANAFLEX-NANO <p>RUSNANO has completed the deal for sale of its share to Danaflex Group. RUSNANO&rsquo;s investments allowed for launching the most advanced production of packaging materials in Russia using nanotechnologies.</p> <p>Construction of Danaflex-Nano&rsquo;s plant began in 2009. Currently, the Company is an absolute leader of the flexible packaging market in Russia.&nbsp;Following the results of 2016, Danaflex-Nano&rsquo;s revenue should amount to approximately 7 billion roubles.</p> <p>The Company&rsquo;s clients include the leading Russian and international manufacturers of food products: Unilever, Nestle, Fritolay, Mondel&eacute;z, Maheev, Efko, Makfa, Mirital, Akkond, and many others.</p> <p>The key advantage of Danaflex-Nano&rsquo;s products is the possibility of considerable decrease in the amount of preservatives and increase in the shelf life of food products and other products packed using such wrap. This is achieved due to considerable decrease of the package permeability for oxygen and other aggressive environmental factors.</p> <p>&ldquo;The Company&rsquo;s success is a fortunate combination of several factors. I will place special emphasis on the contribution of Tatarstan&rsquo;s administration and personally Mr Rustam Minnikhanov who has supported our project from its very start. I hope to continue our cooperation with him in other areas. Tatarstan remains a priority region for us both from the point of view of scientific potential and its industrial opportunities. The second component of success is the entrepreneurial talent of the Company&rsquo;s founder Ayrat Bashirov, who has not only believed in the prospects of new technologies, but accepted the responsibility and risk related to their implementation and bringing them to the market. We expect that after RUSNANO quits the Danaflex project, it will continue demonstrating high growth rates and its commitment to innovations,&rdquo; Chairman of the Board of Management Company RUSNANO <strong>Anatoly Chubais</strong> noted.</p> <p>&ldquo;We have made a dramatic breakthrough due RUSNANO&rsquo;s investments. Recalling the time when our partner entered the project, then we had only flexible packaging production business running.&nbsp;When the deal was completed, we have become a high-tech company on the market both in flexible packaging production and film materials in Russia. From 2012 to 2016, we were annually included in the National Rating of Russian quickly growing technology companies &lsquo;Tekhuspekh&rsquo; (&lsquo;TechUp&rsquo;), We sincerely thank the administration of Tatarstan and RUSNANO for their support rendered to our Company at all stages of the project. Now we are setting new ambitious targets for further drastic development and export of our products to the global markets,&rdquo; the president of the Company DANAFLEX <strong>Ayrat Bashirov</strong> believes.</p> Thu, 15 Dec 2016 12:00:00 +0300 Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention <p>Selecta Biosciences, Inc.&nbsp;(NASDAQ:SELB) today announced that patient dosing has commenced in a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SELA-070, a nicotine vaccine candidate in development for smoking cessation and relapse prevention. The project is being funded primarily by an&nbsp;$8 million&nbsp;grant (#U01DA037592) from the&nbsp;National Institute on Drug Abuse&nbsp;(NIDA), part of NIH.</p> <p>Selecta&rsquo;s Synthetic Vaccine Particles (SVP&trade;) technology is designed to be a versatile platform and is being utilized in a series of programs aimed at inducing either antigen-specific immune tolerance or immune stimulation. SELA-070, an immune stimulation product candidate, delivers nicotine conjugated to the surface of nanoparticles that encapsulate immune stimulating agents. This second-generation product candidate is intended to induce a strong and durable immune response by triggering the production of a high level of anti-nicotine antibodies that bind to the nicotine inhaled by smokers, thus preventing nicotine from crossing the blood-brain barrier and triggering an addictive response.&nbsp;</p> <p>&ldquo;Smoking continues to profoundly impact our society and remains as one of our greatest public health challenges,&rdquo; said&nbsp;<strong>Werner Cautreels</strong>, Ph.D., CEO and Chairman of&nbsp;Selecta. &ldquo;We are very proud and motivated to be teaming with NIDA on this trial to determine if SELA-070 might benefit the millions of smokers in the U.S. and worldwide who are seeking ways to overcome their addiction and improve their health.&rdquo;</p> <p>Approved by the&nbsp;Federal Agency for Medicines and Health Products&nbsp;in&nbsp;Belgium, the Phase 1 trial is a double-blind, placebo-controlled, dose escalation study that is expected to enroll 48 smokers in&nbsp;Belgium. Patients will receive three injections of SELA-070 or a placebo over a period of 12 weeks followed by 8 weeks of monitoring. In addition to safety, the study will evaluate the vaccine&rsquo;s potency through the measurement of concentrations of nicotine-specific antibodies.</p> Thu, 11 May 2017 12:00:00 +0300 RUSNANO’s Portfolio Company Russian Quartz Will Significantly Expand Its Presence on the Global High-purity Quartz Market <p>RUSNANO&rsquo;s portfolio company Russian Quartz has launched the second phase of its quartz deep enrichment plant. Russian Quartz currently produces more than 3 million tons of quartz concentrate per year. After the second phase is put into operation, the production volume will increase threefold, which will allow the company to occupy 15% of the world market, and in the long term&mdash;25%. Thus, Russian Quartz edge out the current market leaders, American companies Unimin and Quartz Corp., and will strengthen its position as a supplier on the global market of high-purity quartz concentrates.</p> <p>Russian Quartz is a project based at the Kyshtym Mining facility. RUSNANO joined the project in 2011 and invested 562 million roubles in it. In 2013, the Japanese financial and industrial holding company Sumitomo Corporation became a co-investor in Russian Quartz. This is the first project that RUSNANO has implemented in cooperation with a Japanese partner. RUSNANO currently owns 28.69% of the company, the same as Sumitomo Corporation. The remaining share belongs to the company management.</p> <p>The share of exports in the Russian Quartz&rsquo; revenue model amounts to 97%. The main foreign markets are China, Japan and the EU. Buyers include international giants such as SUMCO (Japan), Covalent (Japan), Osram (Germany), Philips (Netherlands), and JNC (China).</p> <p>Russian Quartz produces&nbsp;high-purity quartz concentrate, which is used in a number of high-tech industries. The uniqueness of the deposit, as well as the company&rsquo;s specialists&rsquo; know-how pertaining to the enrichment and cleaning of the raw material will allow for obtaining the end product of the highest purity. As a consequence, Kyshtym quartz is part of the international technological production chain of microelectronic chips and solar power plant modules.</p> <p style="text-align: center;"><img alt="" src="" style="width: 100%;" /></p> <p>At the opening ceremony, Chairman of the Board of MC RUSNANO <strong>Anatoly Chubais</strong> said: &ldquo;We are opening the second production line of ultrapure quartz at Russian Quartz plant located in Kyshtym. It is a joint project with our Japanese co-investor, the holding company Sumimoto. What does this mean for us and for the economy as a whole? Increased production and the chance to occupy a quarter of the global market. Moreover, we will put pressure on our serious competitors from the USA. We will strengthen our position in global supply chains in the production of electronics, and reinforce our partnership with global giants. Expanding production will bring 400 new jobs to the region.&rdquo;</p> <p>&ldquo;Our company Sumitomo Corporation (Central Eurasia) LLC is very much excited being involved in the development of Russian Quartz, promising export oriented manufacturer of Russia.&nbsp;Sumitomo Corporation Group, which we are representing in CIS region, is a large Japanese trading conglomerate. Being a Trading company we rather concentrated in exporting Japanese products to Russia in the past,&nbsp;but now our&nbsp;ultimate purpose is to be an established Russian Company and contribute a lot to this Country. In this regard, we wish Russian Quartz a great success having constant guidance and co-operation of our reliable and respected Partners, namely Kyshtym Mining KGOK&nbsp;JSC and RUSNANO,&rdquo; said <strong>Keiji Ikemura, </strong>President and CEO Sumitomo Corporation (Central Eurasia) LLC.</p> Sun, 4 Dec 2016 12:00:00 +0300 RUSNANO and the Ministry of Science and Technology of China Signed a Cooperation Agreement <p>The Agreement was signed in the course of the visit of the Russian President <strong>Vladimir Putin</strong> to China. The Chairman of the Board of RUSNANO <strong>Anatoly Chubais</strong> and the Minister for Science and Technology of the People&#39;s Republic of China <strong>Wan Gang</strong> endorsed the document.</p> <p style="text-align: center;"><img alt="RUSNANO and the Ministry of Science and Technology of China Signed a Cooperation Agreement" src="/upload/images/news/2016-06-25_China.jpg" /></p> <p>The parties have agreed to create a Russian-Chinese High Technology Direct Investment Fund. The Fund is to support the two-way transfer of technologies between China and Russia and import of technologies from third countries for further establishment of industrial enterprises, branches, representative offices and R&amp;D centers in Russia and China.</p> <p>The Agreement also stipulates the establishment of a joint R&amp;D Center or a Nanotech Incubator in Russia and China.</p> <p>&quot;Despite an unfortunate recent downswing in the trade and investment cooperation between our countries, the Russian-Chinese relationship can be unequivocally described as full-fledged and amicable. RUSNANO has been actively and effectively collaborating with Chinese partners, and today&#39;s entering into the Agreement with the Ministry of Science and Technology of China should give our cooperation a new impetus,&quot; stressed Anatoly Chubais.</p> Sat, 25 Jun 2016 12:00:00 +0300 JSFC Sistema and RUSNANO Create a Fund of Direct Investments <p>PJSC JSFC Sistema (hereinafter referred to as the JSFC Sistema) (LSE: SSA, MOEX: AFKS), a public Russian diversified holding company, and RUSNANO announce the start of a joint direct investments fund oriented towards investments in high-technological companies and projects.</p> <p>The total amount of the fund is up to $100 mln. JSFC Sistema and RUSNANO participate in the fund in equal proportion. Resources will be directed to the Fund in proportion to financing of specific transactions.</p> <p>The Fund has been created for 7 years with the possibility of prolongation for three more years. The average amount of one investment is ;5-20 mln. In the future third-party investors will be able to participate in the Fund.</p> <p>The Fund will be involved in investing in high-technological projects at the initial stage as well as in growing and already developed companies in Russia, CIS countries, Europe and Israel. The fund is mainly focused on microelectronics, energy efficiency, robotic technology, information and communication technologies and other fields.&nbsp;</p> <p>&ldquo;RUSNANO has entered into a new stage of the investment cycle, which consists in creation of joint funds to which not only our resources but also resources of professional private investors will be attracted. Thus, we will be more active in promoting the private equity market of high technologies and industry,&rdquo; said the Deputy Chairman of the Board&mdash;Executive Director of Management Company RUSNANO <strong>Boris Podolskiy.</strong></p> Mon, 5 Sep 2016 12:00:00 +0300 Chemist: We Are on the Brink of the Age of Genetic Medicine RIA Novosti, Oct 30, 2016 <h5>American chemist Chad Mirkin, the laureate of the RUSNANOPRIZE 2016, explained RIA Novosti how his nanoparticles will open the age of genetic medicine, may help women get rid of wrinkles and bring us closer to defeating cancer, as well as assured us that the nanomachine-related Apocalypse is a thing of science fiction or deep future.</h5> <p>Chad Mirkin is one of the most renowned American chemists, he&rsquo;s the foremost expert on spherical DNA and RNA molecules and their combination with metal nanoparticles and other inorganic materials. Apart from &lsquo;organic&rsquo; DNA nanoparticles, Mirkin and his team at Northwestern University near Chicago have developed ways of making and printing nanostructures on surfaces for applications in electronics and optics.</p> <p>Mirkin was considered to be one of the top contenders for the Nobel Prize in chemistry in 2013 by the Thomson Reuters bureau and many other experts and has been a contender ever since. He was also nominated in the past for the RUSNANOPRIZE, which is awarded by the Russian nanotech company RUSNANO for development of nanotechnologies and their practical applications since 2009.</p> <div class="img"><img alt="Chad Mirkin" src="" style="height: 397px; width: 700px;" /> <p>Photo: RIA Novosti</p></div> <h4>&mdash; Chad, the geneticists often face a huge backlash by the society and the politicians when they work on DNA editing technologies, such as CRISPR, as well as GMO products. Somehow, nanoparticle research avoided all that; can you explain why did that happen?</h4> <p>&mdash; In this case, I think, there&rsquo;s a fundamental difference between nanoparticle research and GMO research.In the case of nanomaterials, we deal with a subset of chemical research, in which we try to find new and useful properties of different materials that are purely artificial and a consequence of miniaturization. Every bulk material when miniaturized is different. Gold is not gold in color when made on the nanoscale&mdash;it is red. This is why the field is so exciting. Everything becomes new and different when miniaturized, and those differences can be used to develop many new technologies. On the other hand, DNA editing and GMO production is a technique, performed using well-defined biochemical processes and they involve permanently manipulating living organisms. This creates ethical considerations and has drawn the attention of regulators and people concerned about long-term consequences to life itself.</p> <p>Of course, there are people who are afraid of nanotechnologies, but it&rsquo;s really hard and unfair for them to paint all nanotechnologies with the same brush and claim that all of them are bad or good by definition. If you think of it, many things that were created in science in recent years can be called &lsquo;nanotech&rsquo; in one way or another. After all, many molecules, the product of chemistry, are smaller than the building blocks and structures we refer to as nanomaterials.</p> <p>For example, the structures we are working with should not be classified as nanoparticles&mdash;it is too general of a term. They are, as we call them, spherical nucleic acids, a completely new type of nano- and chemical structure, which we can be created by coating specific metallic structures with short strands of DNA or RNA, which allows us to generate particles of pre-determined size, shape and function. There&rsquo;s nothing like them in nature, yet they interact with living matter and cells in unusual and useful ways. They are a triumph of the convergence of chemistry, biology and nanoscience.</p> <h4>&mdash; You were once named as a likely candidate to receive a Nobel prize for your research in the are of DNA nanotechnology. This year it was awarded to a trio of scientists who worked on nanomachines. What do you think about it?</h4> <p>&mdash; Well, this time it was awarded for discoveries that have nothing to do with our research. Feringa, Sauvage and Fraser Stoddart&mdash;my colleague at Northwerstern, by the way&mdash;created the building blocks from which crude molecular machines can be created. These nanomachines replicate in a simplistic manner what macroscale machines or machine parts like rotors and switches can do.</p> <p>So, yes, you can say that this year&rsquo;s Nobel Prize went to nanotech research, but you have to understand that nanotechnology is very vast, and it covers so many things, spanning energy research, electronics, optics and medicine. In this particular case, our research is in a completely different category from what this year&rsquo;s Nobel Prize winners were doing.</p> <p>If we talk about me personally, I have no answer for you&mdash;it&rsquo;s not up to me to decide who and when they should get the Nobel Prize, let&rsquo;s leave that for the Nobel Prize committee.</p> <h4>&mdash; At the Nobel Prize press-conference, Ben Feringa was asked if the nanomachines pose any threat to humanity now or in the future. He told the reporters that he thinks they won&rsquo;t ever be a credible threat for us. Do you think that is true?</h4> <p>&mdash; Again, if we look closely at this year&rsquo;s Nobel Prize, we&rsquo;ll see that it was awarded for a very fundamental discovery. I think that we are now at a very early phase of chemical nanotechnology, and far away from the types of machines that science fiction writers invoke as entities that could cause the extinction of life on Earth in the infamous &lsquo;grey goo&rsquo; scenario.</p> <p>The idea that nanomachines are being built that could rebel is a product of science fiction that has little to do with the actual science. I think this idea will remain in that field of thought for a long time to come. The nanomachines that we have now are really crude demonstrations that can&rsquo;t do anything functional on their own.</p> <p>Generally speaking, they are not the nano-Terminator devices that some propose will cause problems for humanity. In my opinion, decades, if not centuries, will pass before we have to discuss this problem on a serious level, if at all.</p> <h4>&mdash; In which areas of nanotechnologies do you expect the most progress to happen in the nearest future?</h4> <p>&mdash; First, our spherical nucleic acids are being widely used in medicine and the life science industry. Some of them are already used for medical diagnostics in clinics and hospitals&mdash;for example, spherical nucleic acids with gold nanoparticle cores are used as labels for the very precise and fast search of specific DNA sequences, proteins and other types of molecules associated with disease in biological samples.</p> <p>These particles can be used to detect viruses, bacteria or cancer cells in samples of saliva, blood or urine, as well as determining if a patient is genetically predisposed to a specific type of disease. This is all already implemented in practice.</p> <p>Much more awaits us in the future. We are now creating a new kind of spherical nucleic acid that can be filled with other types of molecules, and these particles can infiltrate into cells and tissues like no other DNA or RNA molecules can.</p> <p>For example, we can add those nanoparticles to a kind of cream that you can rub into your skin and that cream can be used to address more than 200 types of genetic diseases that afflict skin cells and tissues. In the same way, we can create medicines that alleviate irritable bowel syndrome in the colon, macular degeneration and other diseases of the eye, or problems with the lungs or bladder. In other words, we are now on the brink of the age of genetic medicine.</p> <p>It&rsquo;s really important to understand that you need three things to make that dream come true. First, we need robust ways of creating and designing DNA and RNA molecules. We learned how to do that about 30 years ago. Second, we need to understand why this or that mutation in a specific gene causes a particular disease. We have this information from the Human Genome Project and related efforts.</p> <p>The third thing&mdash;the ability to get DNA to the place in the body where you need it&mdash;was eluding us until this moment. As it happened, spherical nucleic acids are perfect for that&mdash;now we can target any organ or any tissue in the body, and not only the liver like all other methods of gene regulation therapies. We don&rsquo;t even have to make our particles tissue specific because we can directly and topically apply them to the afflicted organ.</p> <h4>&mdash; Some time ago you managed to turn DNA into crystals. Have you found any practical application for such crystals?</h4> <p>&mdash; If there was a Nobel Prize in this area, I&rsquo;d say that the methods for making such crystals would qualify. We got interested with spherical nucleic acids back in 1996 for reasons that had nothing to do with medicine or biology.</p> <p>We had introduced the concept that you can view nanoparticles as atoms and DNA as a programmable bond and developed the design rules to assemble them into a multitude of crystalline forms. We can mix and match different particles and build crystals with extraordinary complexity from the bottom up.</p> <p>We can control the placement of all these &lsquo;atoms&rsquo; with sub-nanometer precision using the power of DNA bonds. It turned out that it paved the way for an entire new field of materials science, and now we can build materials that we want by designing them to have the properties we desire instead of relying only on what nature offers.</p> <p>Today we have designed nanoparticles that have allowed us to create over 500 different types of crystals, six of which do not even exist in nature. Why is that interesting? Thanks to the diversity of the nanoparticles we have created, the number of such combinations is nearly infinite as well as the new properties that can be realized.</p> <p>Although the practical side of this aspect of spherical nucleic acid research is a decade off, we believe these crystals will be the route to new types of designer catalysts and optical materials and devices that control light in ways we&rsquo;ve never seen before.</p> <h4>&mdash; When you created spherical DNAs, you said that it can be possibly used for cosmetic purposes, i.e. wrinkles removal. Did any of the cosmetics companies contact you?</h4> <p>&mdash; Yes, many corporations approached us. The potential of the spherical nucleic acids is nearly limitless from the cosmetic standpoint&mdash;we can use them to make the skin more elastic, we can use them to remove dark spots in the skin by forcing cells to stop the production of the pigment molecules that make skin go dark, as well as to do many other things.</p> <p>However, there&rsquo;s a problem&mdash;it&rsquo;s not clear how such products will be regulated. They can be viewed as either cosmetics, pharmaceuticals or cosmeceuticals, and it&rsquo;s not clear how their safety will be tested.</p> <p>In addition to that, from a business standpoint and from a health standpoint, the development of cosmetic nanoparticles gives way to disease and cancer research, which is much more important for us and&nbsp; patients than wrinkles or other cosmetic problems.</p> <h4>&mdash; In the recent years scientists published hundreds, if not thousands of papers devoted to this or another &lsquo;material of the future&rsquo;, for example, plasmonics or DNA origami. In time, they sort of &lsquo;evaporated&rsquo; and we don&rsquo;t really hear about those &lsquo;wonder&rsquo; materials anymore. Why does it happen?</h4> <p>&mdash; In fact, I would not say that all such research evaporated&mdash;both plasmonics and origami research are still going strong, although it&rsquo;s probably safe to say that origami in the short term will remain purely a fundamental kind of science. But who knows what will happen 30 years from now?</p> <p>Just remember the story of lasers. When scientists first created lasers, someone said, as far as I remember: &ldquo;this is an interesting discovery that is looking for a use&rdquo;. Decades later, lasers are everywhere&mdash;you can see lasers when you check out your groceries in the supermarket, they are used for conducting surgery in hospitals, each computer and communication system has at least one of them.</p> <p>In other words, sometimes a fundamental kind of discovery takes not only months or years, but decades before it finds its practical and commercial use.</p> Mon, 31 Oct 2016 12:00:00 +0300 RUSNANO Withdraws with Profit from the Project with Mikron <p>RUSNANO proceeds to selling the share in its portfolio company PJSC Mikron (previously OJSC Research Institute for Molecular Electronics (RIME) and Mikron). AFC Sistema acts as the buyer in the deal. The withdrawal will be implemented before the end of 2017. Total income will amount to 8.1 billion rubles.</p> <p>RUSNANO entered the project in 2009 to create on the basis of Mikron a technological line for the production of integrated microcircuits with a topology of 90 nm, which was launched in February 2012. At the end of 2014 the Company released the first domestic dual-core microprocessor &ldquo;Elbrus-2CM&rdquo; developed by CJSC MCST and manufactured using 90-nanometer technology.</p> <p>Today, Mikron is the largest manufacturer of microelectronics in Russia, CIS and Eastern Europe, the only Russian semiconductor manufacturer working on topological norms of 180-90-65 nanometers. Mikron supplies its products to Russian and foreign customers, including communications providers, largest national transportation companies, banks and public authorities and institutions. The range of Mikron products include microprocessors for electronic identification documents, bank cards of NPCS &ldquo;Mir&rdquo; and SIM-cards, RFID-chips and tags for various applications, smart cards on their basis, discrete semiconductors, power management chips and aerospace electronics.</p> <p>&ldquo;I think the project with Mikron is a landmark not only for RUSNANO, but also for the Russian economy as a whole, because microelectronics is the basis for many innovative sectors. Internet of Things, self-driving vehicles, augmented and virtual reality, space, robotics&mdash;it is difficult to find a modern sector without an electronic microchip in its core. Moreover, the creation of its own microelectronic base is also the issue of stability and competitiveness of the country. I also want to note that in our project AFK Sistema has shown itself as a reliable and professional partner, and we look forward to further mutually beneficial cooperation,&rdquo; said<strong> Oleg Kiselev</strong>, Deputy Chairman of the Board of the Management Company RUSNANO.</p> Mon, 31 Oct 2016 12:00:00 +0300 RUSNANO Transfers Russian Representative Powers to Kurchatov Institute in XFEL Project <p>In accordance with the RF Government decree of May 18, RUSNANO transfers its shares in the international European X-ray free electron laser (XFEL) project to the National Research Centre Kurchatov Institute.</p> <p>The XFEL X-ray laser is a unique research project involving 11 countries. The facility will generate femtosecond flashes of high-energy radiation, which will allow scientists to investigate the structure of biological molecules and a variety of materials, and monitor ultrafast biological and chemical processes. The X-ray laser is composed of an electron accelerator and undulators (magnets) which will deflect the electrons from the rectilinear trajectories, thereby causing the emission of synchrotron radiation.</p> <p>The decision to create the facility was made in April 2009. The construction of the six-kilometre system of tunnels and underground experimental halls for the XFEL is already finished. Now, the experimental equipment is being installed on the site. It is expected that the first experiments at XFEL will begin in April 2017.</p> <p>In 2009, Russia became one of the 11 participating countries; it was represented by JSC &ldquo;RUSNANO&rdquo;, whose share in the capital of the European XFEL GmbH totalled 26.24 percent. By order of the Government of the Russian Federation, RUSNANO invested on behalf of Russia in the construction of the XFEL, and in turn, the Kurchatov Institute carried out the scientific management of the project. The collaboration between RUSNANO and the Kurchatov Institute not only facilitated the participation of Russian researchers in shaping of the XFEL research program, but also created orders for Russian companies for the equipment and materials needed for the construction of the facility.</p> <p>As the project moves from the construction stage to the actual solving of operational issues, the Russian government decided to transfer the powers in the project from RUSNANO to the National Research Centre Kurchatov Institute.</p> Mon, 30 May 2016 12:00:00 +0300 Hevel Group Modernized the Plant and Increased the Volume of Solar Modules Production Two Times <p>Hevel Group (joint venture of Renova Group and RUSNANO) completed the modernization of the production line and increased the manufacturing complex capacity up to 160 MW per year. That volume of production will allow to satisfy 50% of the current demand at the Russian market of solar energy.</p> <p>The plant began production of solar module using a radically new technology: heterostructure technology. It differs from the majority of analogues by the highest efficiency of electricity production: the average efficiency coefficient of cells makes more than 22%. Moreover, new modules are more efficient in diffused light and at high and low temperatures, which significantly extends the geography of their application.</p> <p>&ldquo;With respect to majority of parameters our solar modules are considerably superior to their world analogues in the silicone segment&rdquo;, said the General Director of Hevel Group, <strong>Igor Shakhray</strong>. &ldquo;More than double increase of solar modules efficiency as compared to the previous technology allows to cut down expenses significantly not only for production of panels, but also for building of solar plants, which opens wide prospects with regard to implementation of large-scale projects both in Russia and abroad&rdquo;.</p> <p>One of the advantages of the plant is the flexibility of the production process: now, the manufacturing line produces not only solar modules, but also high-efficiency cells that can be exported for assembling of modules in the country, where solar plants are built.</p> Mon, 3 Jul 2017 12:00:00 +0300 10% of Saint Petersburg’s Trolleybus Fleet Will Get Lithium-ion Accumulator Batteries from Liotech <h5>Liotech-Innovations Ltd will deliver 66 vehicle sets of lithium-ion accumulator batteries (LIAB) for Russian trolleybus manufacturer TROLZA. The project is implemented under the contract between Trolza and the Transport Committee of Saint Petersburg for delivery of trolleybuses with extended autonomous travel distance for the purpose of renewal of urban electric transport.</h5> <p>Currently, there are 46 trolleybus routes in the city, and the fleet consists of more than 600 trolleybuses. Therefore, 10% of the trolleybus fleet will be equipped with lithium-ion accumulator batteries produced by Liotech-Innovations Ltd. All vehicles that will be delivered under the contract have autonomous cruising range of 7.5 km.</p> <p>&ldquo;The increasing number of trolleybuses with extended autonomous travel distance on the Russian roads is an important stage of electric transport evolution allowing to create in Russia competencies in development and manufacturing accumulators with power capacity up to 100 kWh and to move subsequently to production of more powerful (200-400 kWh) accumulators for their usage in electrobuses and other heavy vehicles. This is also convenient for the urban operating companies&mdash;they get an opportunity to test-operate vehicles with autonomous electric movement and to use that experience in introduction of electrobuses&rdquo;, said the managing director for investment activity of MC ROSNANO, <strong>Vladimir Kozlov</strong>.</p> <p>According to the forecasts, by 2025 the total storage capacity of accumulators of urban transport will make more than 10 GWh. Under the contract Liotech-Innovations produces and delivers not only lithium-ion accumulators, but also top-level engineering solutions: accumulator battery embedding custom-made frame and management and temperature control system. Currently, Liotech is the center of Russian competencies in mass production of lithium-ion cells and batteries made of such cells.</p> <p>&ldquo;Development of cooperation with Trolza means for us recognition of quality and efficiency of our products. In addition to 66 vehicle sets for trolleybuses, a large consignment of trolleybuses with autonomous travel distance will be delivered by Trolza for their use in the Southern Federal District. We are not going to stop at what has been accomplished and actively present the products of Liotech-Innovations Ltd. at leading international technological exhibitions. For example, by the end of the year the number of electric transport with increased autonomous travel distance equipped with LIAB&rsquo;s produced by Liotech-Innovations will be approximately 150 units. Liotech-Innovations Ltd is busy with work, the number of employees at the enterprise is increasing and has already reached 200 persons&rdquo;, noted the General Director of Liotech-Innovations Ltd. <strong>Valery Yarmoshchuk</strong>.</p> <p>Liotech supplies the energy market. In early 2017, another RUSNANO portfolio company Hevel launched the hybrid electric power plant (AHEP) in Menza village, Trans-Baikal Territory, Russia. AHEP consists of solar modules of 120 kW in total power, and two diesel generators of 200 kW each. The accumulator cells for the power storage device with 300 kWh capacity produced by Liotech were used for the electric power plant development. As planned, in 2017, Hevel will build two more hybrid electric power plants in the Trans-Baikal Territory, Russia, where Liotech power storage devices can also be used as a completely finished containerized product, including all electronic and control systems (the supplier&rsquo;s choice will be defined upon the tender). The latest plant&rsquo;s innovations will be used for Liotech power storage devices with a full quality assurance.</p> <p>Furthermore, the Russian producers of commercial transport vehicles inquire delivery of LIAB sets both for electric motor vehicles, electric buses, and special equipment. At this moment, the finished solutions for other specialized machinery are also being developed, in particular, for the mining industry.</p> <p>In early June, Liotech-Innovations took part in the International Specialized Exhibition of Mining Technologies named &ldquo;Coal of Russia and Mining 2017&rdquo;, where more than 400 companies, including more than 100 foreign manufacturers of vehicles and mining equipment, showed their developments. At that exhibition Liotech-Innovations presented its LIAB in RV for AM8D mining electric locomotive. Foreign partners&mdash;equipment manufacturers showed interest in respect of the company&rsquo;s products noting the sustainability of implementation and development of lithium-ion technologies in the nearest 20 years.</p> Mon, 3 Jul 2017 12:00:00 +0300 RUSNANO’s Portfolio Company Advenira Launched Production in Kazan <h5>The enterprise located in the territory of KhimGrad technological park started production of chemical agents for application of multi-field coatings. Potential clients include machinery, pipe and aerospace companies of the country.</h5> <p>Advenira Enterprises, Inc. has been founded in 2010 in the Silicon Valley by a group of Russian specialists headed by Elmira Ryabova. In December 2011, RUSNANO has become one of the company&rsquo;s shareholders and up to this day it has invested more than RUB 1 bln.</p> <p style="text-align: center;"><img alt="" src="" /></p> <p>Advenira develops both the coating equipment and precursors (chemicals, solutions). Advenira creates anticorrosive coatings for oil and gas, automotive and machine-building industries, protective coatings for touch screens, automobile and energy-saving glasses as well as for solar batteries.</p> <p>The volume of the global market of coatings makes more than $50 bln and about a half falls on anticorrosive coatings.</p> <p>The company&rsquo;s know-how protected by a number of patents allows to apply films on large and complex objects of almost any composition whether it be glass, metal, plastic or even wood. The major part of the existing coating application processes requires deep vacuum and high temperature for precipitation, which is associated with high energy consumption. The patented films of Advenira are cost effective as they are used at room temperature and atmospheric pressure on a high performance conveyor line.</p> <p>This results in plant cost reduction (by 3-5 times) and reduction of the cost of a square meter of coating (up to 10 times) due to high performance, efficiency and low energy consumption, as well as better characteristics of the coatings (transparency, barrier properties, erosion resistance, etc.) in comparison with other application methods.</p> <p>&ldquo;Six years ago, when we saw the work of Elmira Anatolyevna Ryabova in the Silicon Valley we were highly impressed. To say the truth, by that time it were several cans with something boiling and bubbling inside. And it wasn&rsquo;t something very large. But the essence of that technology is amazing. This is about coatings that do not require vacuum and high temperature for application. The main know-hows are the composition and the method of application. The range of application and the surfaces is very broad, and the potential of that technology is great. A minor production with the capacity of 30 thousand litres per year is being launched at the moment. The next step is 300 thousand litres. The potential consumers range from automotive industry, including KAMAZ Group (we are conducting negotiations with it), to petrochemical industry, covering of bridges and even monuments&rdquo;, said the Chairman of the Board of MC RUSNANO, <strong>Anatoly Chubais.</strong></p> <p>Advenira launches a site in the territory of KhimGrad technological park for production of chemical agents (precursors) for coatings. It is planned that in the near future the equipment for application of coatings will be installed at the same site. At the first stage, the volume of chemical agents&rsquo; production will not exceed 30 thousand litres per year, but subsequently the volume will be increased 10 times.</p> <p>Advenira&rsquo;s products and services have already aroused the interest of a number of Russian players from several industries that intend to use the company&rsquo;s coatings for extension of service life of their products and reduction of costs. In particular, the company signed agreements of intent with OZ company, which produces anticorrosive and fire retardant coatings for metal structures and concrete, with Milandr&mdash;leading Russian developer and manufacturer of integrated circuits, and with RMA Rus&mdash;manufacturer of stop valves for pipelines.</p> <p>&ldquo;The market of functional and protective coatings is growing incredibly fast. This is explained by the companies&rsquo; endeavours not only to reduce costs by extending the service life of their products and to extend the range their properties, but also to minimize the negative effect of industry on the environment. Advenira is trying to solve these two problems. And, as far as we can see, Elmira Ryabova&rsquo;s company has achieved tangible results. For that reason, we in OZ believe that our joint efforts in development of coatings and their application technologies will let us generate a technological solution allowing to ensure a durable protection of our customers&rsquo; products, while preserving non-renewable natural resources and the ecosphere of the Earth&rdquo;, said the General Director of OZ GROUP LLC, <strong>Grigory Shifrin</strong>.</p> <p>In March 2016, Advenira established its first enterprise in Russia, in the territory of New Moscow, Troitsk, at the site of TechnoSpark nanotechnological center. The aim of Advenira center is the promotion of nanocomposite materials at the Russian market by means of implementation of functional coatings in various industries. The center has nanotechnological equipment for precision and uniform application thin films with thickness of 3 to 10 microns and more heavy coatings (up to 100 microns) on plain bases and details with complex geometry. The center uses necessary equipment for preparation of surface before application of coatings and laboratory instruments for control over the characteristics coating solutions.</p> <h2>Technical Information</h2> <p>Currently, there are several standard approaches to application of functional nanocomposite films. This is physical vapour deposition (<strong>PVD</strong>), &nbsp;&nbsp;&nbsp; chemical vapour deposition (<strong>CVD</strong>) and some methods for a limited number of liquids, in particular, sol-gel process, which ensures unique advantages, but is not widely used due to significant shortcomings where the short life of precursor solutions is the main one. The <strong>SDN</strong> (Solution Derived Nanocomposite) technology is a modification of the sol-gel method that has overcome problems maintaining the precursor solution in its initial state.</p> Mon, 26 Jun 2017 12:00:00 +0300 Quantenna Communications Launches Initial Public Offering <p>Quantenna Communications, Inc. (&ldquo;Quantenna&rdquo;), a provider of high-performance Wi-Fi solutions, today announced that it expects to launch the initial public offering (IPO) of its common stock on October 17, 2016. The offering is for 6.7 million shares at an initial price range of $14.00 to $16.00 per share. The Company also expects to grant the underwriters an option to purchase up to 1,005,000 additional shares.</p> <p>Quantenna has applied to list its common stock on the NASDAQ Global Select Market under the ticker symbol QTNA. Morgan Stanley, Barclays and Deutsche Bank Securities are acting as joint bookrunners for the transaction. Needham &amp; Company, William Blair, and Roth Capital Partners are acting as co-managers.</p> <p>The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained from: Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at <a href=""></a>; or from Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005, by telephone: 1-800-503-4611, or by email at <a href=""></a>.</p> <p>A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p> Mon, 17 Oct 2016 12:00:00 +0300 Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) <p>Selecta Biosciences, Inc.&nbsp;(NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced new preclinical data regarding non-immunogenic gene therapies that were presented at the&nbsp;American Society of Gene &amp; Cell Therapy&nbsp;(ASGCT) 2017 Annual Meeting, which took place last week in&nbsp;Washington, D.C.</p> <p>&ldquo;Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,&rdquo; said&nbsp;<strong>Werner Cautreels</strong>, Ph.D., CEO and Chairman of&nbsp;Selecta. &ldquo;Together with various collaborators, we have again demonstrated the potential of Selecta&rsquo;s proprietary immune tolerance Synthetic Vaccine Particles (SVP&trade;) technology, which is designed to improve the clinical benefits and transform the development of gene therapy. We also were pleased with the presentation of preclinical proof-of-concept data for our proprietary product candidate in MMA, a life-threatening rare disease that can only be treated today by diet or organ transplantation.&rdquo;</p> <p>A team led by&nbsp;<strong>Charles Venditti</strong>, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the&nbsp;National Human Genome Research Institute&nbsp;at the&nbsp;National Institutes of Health, and&nbsp;<strong>Luk Vandenberghe</strong>, Ph.D., Director of the&nbsp;Grousbeck Gene Therapy Center&nbsp;at Mass. Eye and Ear and an Assistant Professor at&nbsp;Harvard Medical School, delivered a presentation entitled &ldquo;Anc80 Mediates Hepatic Correction of Methylmalonyl-CoA Mutase Deficiency in Murine Models of Methymalonic Acidemia.&rdquo; This presentation featured data from mouse models of MMA, a rare inborn error of metabolism most frequently caused by mutations in the enzyme methylmalonyl-CoA mutase (MUT). In this study, MUT-deficient mice were treated with Selecta&rsquo;s Anc80-synMUT product candidate to express the human MUT gene. The gene therapy induced a robust biochemical and clinical response as plasma methylmalonic acid levels dropped precipitously, substantial weight gain ensued and survival was sustained. Further, presented data indicate that the combination of SVP and Anc80 could effectively overcome the immunogenicity that has limited other gene therapy programs by enabling enrollment of patients with pre-existing antibodies to AAV and keeping patients eligible for repeat administration.</p> <p>A team led by&nbsp;<strong>Federico Mingozzi</strong>, Ph.D., Head of Immunology and Liver Gene Therapy at Genethon, delivered a presentation entitled &ldquo;Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via&nbsp;Repeated Co-Administration&nbsp;of Vector with Rapamycin Tolerogenic Nanoparticles.&rdquo; This presentation featured data from both mouse and non-human primate studies demonstrating how the co-administration of SVP-Rapamycin completely blocked anti-AAV immune responses in an antigen-specific manner and allowed for vector re-administration and gene therapy dose titration. The ability to dose titrate could provide for more effective development and administration of gene therapies.</p> Mon, 15 May 2017 12:00:00 +0300 The Development by RUSNANO Portfolio Company OptoSense Will Allow to Significantly Reduce Coal Mine Accidents <h5>OptoSense proceeds to delivery of hydrocarbon sensor with the lowest ever power consumption.</h5> <p>OptoSense, RUSNANO portfolio company, has begun commercial delivery of the most advanced infra red hydrocarbon sensors MIPEX-04, that, among other things, will be used for provision of the miners&rsquo; personal safety. It is no secret that the miners still die as a result of methane explosions in coal mines. A revolutionary development by OptoSense will allow preventing the accidents much more effectively, thus saving lots of human lives.</p> <p>Power consumption of the innovative sensors is 1000 times less than that of the competing analogues, which means that the devices in use can operate for over 2 years on a single charge instead of several hours. Leading international players in the market of industrial safety such as Honeywell Analytics, which has already started to sell personal gas analysers based on the sensor, are among the buyers of MIPEX-04.</p> <p>New generation of sensors created by OptoSense consumes less than 100 microwatt of power which opens the door to multiple opportunities for development of the most advanced devices and solutions to detect and measure explosive gas concentrations, including the creation of the new market of portable clip gas analysers &ldquo;from scratch&rdquo;.</p> <p>The unique features of new sensors have become possible thanks to semi-conductive polycrystal nanoscale layers in the mass fabrication of the sensor key elements, namely light-emitting diode sources and photovoltaic detectors. It is the availability of MIPEX-04 that allowed achieving such outstanding parameters of time of operation of the final device without the need for maintenance during the service life for the first time in the international practice.</p> <p>OptoSense specializes in manufacturing of infrared optical sensors to determine explosive gas concentrations, primarily, hydrocarbons. Up to now, almost 100 international and Russian producers of gas analysers are the company&rsquo;s customers. Furthermore, almost 70% of the company&rsquo;s products are sold in the USA and Europe.</p> <p>Gas analysers based on OptoSense sensors are used to provide personal and industrial safety in oil and gas or petrochemical industry (extraction, transportation and processing of oil and gas), coal mining (in mines), power industry (gas-fired plants), telecommunications (maintenance of underground cable networks). The total scope of gas analyser market as estimated by Frost &amp; Sullivan is about $2 billion with potential increase to $3 billion by 2018.</p> Mon, 13 Feb 2017 12:00:00 +0300 Having Got Double Return of Investments, RUSNANO Exits the Magnesium Oxide and Hydroxide Production Project <p>RUSNANO sells its ownership interest in the NikoMag portfolio company, specializing in production of <nobr>nano-structured</nobr> magnesium hydroxide (a fireproofing additive, the substance inhibiting inflammation and fuming processes), <nobr>high-purity</nobr> magnesium oxide (used in production of transformer steel and general mechanical rubber goods) and magnesium chloride used in oil- and <nobr>gas-production,</nobr> production of construction materials and in ice control activities.</p> <p>The total project budget amounts to RUB 3.8&nbsp;bln, including the RUSNANO ownership interest of RUB 1.3&nbsp;bln. The purchaser of the RUSNANO ownership interest is the Group of Companies NIKOCHEM. Proceeds from this transaction are 200% greater than the investments made.</p> <p>RUSNANO entered the project in 2010. During this time, there was built, equipped, and developed to its project capacity a unique plant, having no equals in Russia, occupying the area of 4.5&nbsp;ha, and currently employing 262&nbsp;employees.</p> <p>The production capacity for magnesium hydroxide is 25&nbsp;thousand tons a year; for magnesium oxide, 30&nbsp;thousand tons a year. Before launching NikoMag, both products were wholly imported into Russia. In the nearest future, the company plans to occupy almost 100% of the Russian synthetic magnesium hydroxide market and 90% of the <nobr>high-purity</nobr> magnesium oxide market. NikoMag is included into the import substitution action plan for the chemical industry approved by the Ministry of Industry and Trade of the Russian Federation.</p> <p>NikoMag&rsquo;s products have a considerable export potential. The magnesium hydroxide and oxide, currently produced at the enterprise, are being tested at plants producing incombustible compositions, fuel oil additives, and catalytic agents in foreign countries, including the USA, India, and Denmark. Several large contracts on supply of magnesium hydroxide and oxide to Asian markets have already been executed, and about 1,500&nbsp;tons have been shipped.</p> <p>&ldquo;Having visited the NikoMag site, I was greatly impressed by the highest technological level of production. As of today, the production plant in Volgograd is the most advanced in the world in terms of used engineering solutions, process configuration and management. Following the negotiations, a <nobr>long-term</nobr> contract was signed on supply of NikoMag magnesium hydroxide and oxide to the Chinese market. Considering the excellent quality level, I think highly of prospects for the <nobr>Russian-made</nobr> products to enter Asian markets,&rdquo; said Mr. <strong>Yan Li</strong>, General Director of SINOPEC International Company Rus LLC.</p> <p>&ldquo;One of the success factors for this project is the effective choice of the niche, where the Company was able to propose a high quality product for a competitive price. Initially, we focused on it since we believe that the medium capacity chemistry sector in the Russian Federation has a very high potential and very high level of competitive capabilities on the global market. However, despite of strong fundamental indexes and availability of raw material base, it has been significantly undercapitalized recently; therefore, Russia imports chemical products for over $30&nbsp;bln at the moment. Subsequently, we expect emergence of attractive new projects and activation of strategic players in this area,&rdquo; pointed Mr. <strong>Dmitry Pimkin, </strong>Managing Director of Management Company RUSNANO LLC.</p> Mon, 1 Aug 2016 12:00:00 +0300 Over the Period of Three Years, More Than 10,000 Persons Passed Examination in PET-Center in Ufa <h5>The PET-Center in Ufa started reception of patients in March 2014 and became the first center commissioned by RUSNANO&rsquo;s portfolio company PET-Technology. For three years of operation more than 10,000 persons passed PET/CT-diagnostics of oncological diseases. As of June 2017, more than 41,000 persons were checked up in the federal network.</h5> <p>According to the statistics, the number of oncology patients in Russia is increasing by half a million persons every year. The technology of PET/CT-scanning (positron emission tomography coupled with computerized tomography) allows to detect cancer at early stages, when the patient has a chance of complete recovery.</p> <p>PET-Center of PET-Technology in Ufa is located in the territory of one of the largest specialized oncologic dispensaries in Russia, which for the period of its existence has provided assistance to many thousands of patients suffering from virtually any types oncological diseases.</p> <p>&ldquo;A great work has been done during three years from the moment of opening of the center in Ufa. The residents of the Republic of Bashkortostan and the Volga Federal District gained access to high-tech medical aid in the form of diagnostics and treatment of oncological diseases. The center rendered assistance to tens of thousands persons. These are not just dry figures for us&mdash;these are saved lives. This is not only our merit; we would not achieve that result without support of local doctors and regional authorities. We hope that we will keep the pace in future&rdquo;, noted the managing director for the investment activity of the Management Company RUSNANO, <strong>Olga Shpichko.</strong></p> <p>&ldquo;It took PET-Technology just a few years to create the network of nuclear medicine centers and become the leader in the sphere of diagnostics opportunities of nuclear medicine. The Ufa center was the first center, which started reception of patients in 2014. We are grateful to the administration of the Republic of Bashkortostan for its all-round support in organization, creation and operation of the center of nuclear medicine in Ufa. Only through joint efforts we can change the lives of tens of thousands of oncologic patient that need modern diagnostic techniques&rdquo;, said the General Director of PET-Technology, <strong>Diana Kobesova</strong>.</p> <p>In-house production of radiopharmaceuticals used in diagnostics, quality control laboratory, modern PET/CT-scanner and the high level of training of specialists guarantee precision and accuracy of the examination.</p> <p>&ldquo;We successfully diagnose tumors that can hardly be diagnosed by other diagnostic techniques. The majority of our patients have neoplasms in lungs, brain, mamma, prostata gland and lymphomas&rdquo;, says radiotherapist, radiologist of the Ufa center, <strong>Guzel Muslyumova</strong>.</p> <p>Patients can pass diagnostics in the PET-center in Ufa under the Program of State Guarantees of Free Medical Aid to Citizens, voluntary medical insurance programs or at their own expense.</p> <p>Currently, the federal network of PET-Technology includes eight PET-Centers located in Moscow, Ufa, Ekaterinburg, Lipetsk, Belgorod, Tambov, Kursk and Orel. As of June 2017, more than 41,000 persons were checked up in the federal network.</p> Fri, 9 Jun 2017 12:00:00 +0300 “This Thought Seems to Me Crazy Enough to Discuss It”. Anatoly Chubais about Fundamental Trends of Human Development. Speech at 13th STS Forum, Kyoto, Japan <p><strong>Dear Chairmen, esteemed colleagues!</strong></p> <p>My short speech on sustainable development I will try to divide in two parts: first is about the digital world and another on material world. I believe, sustainable development cannot be understood without understanding those two parts of the modern technological revolution. Certainly, I&rsquo;ll not pretend for comprehensive analysis, but just for snatching out single trend in each of them.</p> <p>Digital part, the ICT, is huge and comprehensive. Probably the most frequently discussed here is the topic of self-driving. Self-driving cars, self-driving tracks, self-driving ships, trains, helicopters, planes. What does it means in reality? That the ICT start to be able to operate in a very specific sectors of high human responsibility. I would say even more: on the previous stage of the ICT revolution computer helped human, but now it starts to substitute human. Reminds industrial revolution here, when machines, mechanisms, engines start to help and then substitute workers in what they were doing. But in that time, in time of industrial revolution mechanisms substitute human in physical capacity, and now it starts to substitute human in intellectual capacity.</p> <p>This fundamental deepness on interference of ICT in human activities will have strong and fundamental outcomes on sustainability. In this context we are discussing a robotization, we are discussing a labor market, we are discussing a rate of unemployment, etc. But I want to ask myself, what will be the next sector of human activity, what will be the next occupation, which can be substituted by the computer, by the ICT?</p> <p>Speaking about self-driving cars, I said that this is the sector of decision making with very high responsibility. So what next? What is the next sector of decision making with high responsibility? Being a manager myself, maybe the next sector where computer will start to substitute human will be&hellip; management?</p> <p>I don&rsquo;t think I am speaking about the years, but may be about the decades. Management, as we all know, is very comprehensive and diversified type of occupation, so maybe there are some less sophisticated management levels will be substituted first, and then stage by stage it will go further. If that&rsquo;s true, maybe the next era coming and we will call it &ldquo;Demanagerization&rdquo;? If we are speaking now about unmanned driven vehicles, why we she&rsquo;ll not speak about unmannedmanaged companies? Why not think about the next stage of ICT revolution which one may call &ldquo;demanagerization of human activity&rdquo;. For me this idea sounds crazy enough to be discussed here.</p> <p>That&rsquo;s the possible trend in digital part of sustainable development.</p> <p>As we come to the material part of the sustainable development, one word coming to my mind is the word suggested by famous economist, philosopher, and writer Vaclav Smil: in his recent book he suggested the term &ldquo;Dematerialization&rdquo;. If this term meaning would be decline of global material and energy demand, based on new materials with upgraded physical, mechanical, electrical properties, it may present fundamental trend in material world.</p> <p>On the previous STS Forum I was privileged to speak here about the nanotechnology, about nano-augmented materials. It is well known that if some nanoparticles, like carbon nanotubes, will be added in proportion less than 1%, to the plastic, cement and metal, they will strongly affect final material mechanical, physical and electric property. That is what we are doing in Russia. And one of our companies&mdash;OCSiAl&mdash;which is able to produce Single Wall Carbon Nanotubes in industrial scale technology step by step started to develop this market. So we are currently working with 5 of top 10 manufactures of lithium-ion batteries (increasing life-cycle of lithium-ion batteries), elastomer producer (making elastomer electrically conductive), with 8 of top 10 paintings and coating manufactures, with the drone manufactures, with the global chemical companies, with transparent conductive film producers, car and aircraft producers. All these huge markets are start to open stage by stage just last year. Situation strongly changed this year versus what I was able to speak about here last year. In the year 2016 we are tripling production and the sales of the company. And if we commissioned last year first in the world the 5-tonn of SWCNT reactor, now we are building the next with the 50-tonn capacity SWCNT reactor. Why? Because we believe, there is something that may really make basic material much lighter, much stronger, to reduce the amount of materials, to save energy and that will generate fundamental positive impact on the sustainability. There are three basic materials the human designed world consist from&mdash;metal, cement and plastic. If we will be able to produce them lighter and stronger, that is something what can bring strong upgrade on sustainability in a global sense.</p> <p>Am I wrong or am I right speaking about the demanagerization? That&rsquo;s the part where I just want to be provocative, following the instruction of our chairman. When I speak about dematerialization&mdash;new materials, nano-augmented materials&mdash;I&rsquo;ve tried to go from hypothesis to facts and forecasts. That is something what we work on and I hope we will be able to share with scientists, business leaders, politicians, anybody of the audience. Anyhow, the trends for demanagerization in digital world and for dematerialization in material world may become point for discussion on this forum.</p> <h5><a href="">Текст выступления Анатолия Чубайса на 13-м Международном форуме науки и&nbsp;технологии в&nbsp;обществе (STS&nbsp;Forum) в&nbsp;Киото, Япония</a></h5> Fri, 7 Oct 2016 12:00:00 +0300 Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout <ul> <li><em>First Immunotherapeutic Candidate to Leverage Selecta&rsquo;s Proprietary Synthetic Vaccine Particle (SVP&trade;) Platform</em></li> <li><em>SEL-212 Targeting Unmet Needs of Chronic Refractory and Tophaceous Gout Patients</em></li> <li><em>Initial Phase 2 Trial Results Expected in First Half of 2017</em></li></ul> <p>Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the company&rsquo;s lead proprietary immunotherapeutic product candidate for the treatment of chronic gout in patients refractory to conventional therapy. This trial will assess the safety, tolerability and clinical activity of SEL-212, a combination product candidate consisting of pegsiticase (pegylated uricase) and SVP-Rapamycin. SEL-212 is designed to be the first non-immunogenic enzyme therapy for gout. Initial results from this trial are expected in the first half of 2017.</p> <p>&ldquo;SEL-212 has the potential to address the large unmet need of severe gout patients, who are currently lacking effective treatment options. By lowering serum uric acid levels and total body uric acid burden with multiple doses of SEL-212 covering up to 6 months of treatment, SEL-212 is designed to eliminate inflammatory deposits that cause debilitating pain and often serious damage to joints and organs,&rdquo; said&nbsp;<strong>Earl Sands</strong>, M.D., Selecta&rsquo;s Chief Medical Officer. &ldquo;The initiation of this trial marks an important advancement for our Synthetic Vaccine Particles (SVP) immunotherapeutic platform, which has the potential to enable and enhance a large number of biologic therapies including enzyme therapies, gene therapies and biologic cancer treatments by antigen-specific mitigation of undesired immune responses such as neutralizing antibodies.&rdquo;</p> <p>This Phase 2 clinical trial of SEL-212 is being conducted at 15 centers in&nbsp;the United States&nbsp;and is expected to enroll more than 36 symptomatic gout patients with elevated uric acid levels. The primary and secondary endpoints of the trial include safety and tolerability of multiple doses of SEL-212, reduction of serum uric acid levels and mitigation of anti-drug antibodies (ADAs). Exploratory endpoints include measurement of uric acid deposits by Dual Energy Computed Tomography (DECT) imaging. Multiple dose treatment with SEL-212 has the potential to significantly lower total uric acid crystal burden in joints and tissues, which cannot be effectively or rapidly achieved by oral gout therapy. The removal of the uric acid crystal deposits is expected to reduce overall inflammation and the frequency of debilitating gout flares.&nbsp;&nbsp;</p> <p>SEL-212 exemplifies Selecta&rsquo;s strategy to combine its SVP-Rapamycin platform with targeted biologics that require repeat administration to prevent the formation of ADAs. Undesired immune responses such as ADAs are a common complication with biologics including enzyme therapies, gene therapies, and cancer treatments. Application of the SVP platform may yield a pipeline of products with improved therapeutic benefit resulting from the reduction of unwanted immune responses.&nbsp;Selectaaims to advance a series of programs, including novel gene therapy products.</p> <h3>Phase 1 Data to be Presented&nbsp;December 7-8, 2016</h3> <p>In the Phase 1 clinical program of SEL-212, active and generally well-tolerated doses of pegsiticase and SVP-Rapamycin were identified in two single ascending dose trials with more than 75 patients. SVP-Rapamycin prevented the formation of ADAs and enabled pegsiticase to maintain sustained control of serum uric acid levels for at least 30 days after a single dose.</p> <p>On&nbsp;Wednesday, December 7, 2016&nbsp;at the 11th Annual Immunization and Vaccine Summit (IMVACS) in&nbsp;Boston, MA,&nbsp;Selecta&nbsp;will present results from this Phase 1 program. These results will also be discussed on a live conference call and webcast on&nbsp;Thursday, December 8, 2016&nbsp;at&nbsp;8:30 a.m. ET.</p> Fri, 28 Oct 2016 12:00:00 +0300 RUSNANO and KuibyshevAzot Start an Energy-efficient Caprolactam Production <p>KuibyshevAzot finished the large-scale project for modernization of caprolactam production (used for production of nylon and nylon-based products&mdash;industrial yarn and fabrics) based on advanced technologies with the use of nanostructured catalysts. Total investments in the project, which is being implemented in cooperation with RUSNANO, amounted to RUB 9.8 bln, including the RUSNANO co-funding in the amount of RUB 1.25 bln.</p> <div class="img"><img alt="RUSNANO and KuibyshevAzot start an energy-efficient caprolactam production" src="/upload/images/news/2016-08-26_KuibyshevAzot_700.jpg" /> <p>RUSNANO and KuibyshevAzot start an energy-efficient caprolactam production</p></div> <p>The Governor of the Samara Region <strong>Nikolai Merkushkin</strong>, the General Director of KuibyshevAzot JSC <strong>Alexander Gerasimenko</strong> and the Chairman of the Executive Board of RUSNANO MC <strong>Anatoly Chubais</strong> took part in the production launch ceremony.</p> <p>The Dutch group Royal DSM N.V., the global leader in development and production of high-technology materials and chemicals, made a technology transfer within the framework of the project: nanostructured catalysts are used in a number of key caprolactam synthesis processes. The implementation of know-how reduced the final production cost by 12%. The RUSNANO investments allowed increasing KuibyshevAzot&rsquo;s caprolactam production capacity from 190 to 210 thousand tonnes per year, and later&mdash;to 260 thousand tonnes per year.</p> <p>Construction and launch of the energy-efficient caprolactam production will allow the company to grow the production of its derivatives: polyamide-6 (nylon), industrial and filament yarns, cord fabric (used to make fiber glass). The project is among the Volga Federal District priorities.</p> <p>The project implementation will allow lowering the consumption of fuel gas (by 2.4 mln m<sup>3</sup> per year) and electric energy (3.2 MW per year), as well as reducing greenhouse gas emissions by 200 thousand tonnes per year, and incinerable wastes by 21%.</p> <p>KuibyshevAzot is in the top ten of national nitrogen industry plants and is the leader of the caprolactam and polyamide-6 production in the CIS and Eastern Europe. The company also produces 5% of all Russian fertilizers. KuibyshevAzot carries out operations in two main areas: caprolactam and its derivatives (polyamide-6, industrial and filament polyamide yarns, cord fabric, engineering plastics) and ammonia and nitrogen fertilizers (carbamide, ammonium nitrate, ammonium sulfate).</p> <p>&ldquo;Cooperation between RUSNANO and DSM facilitates the realization of our strategic plans on consolidation of leading positions on the caprolactam and polyamide markets and expansion of processing of these products within Russia. Utilization of nanotechnologies and technologies of leading global licensers will allow us to increase operating efficiency and competitiveness of the plant,&rdquo; said the General Director of the KuibyshevAzot JSC <strong>Alexander Gerasimenko</strong>.</p> <p>&ldquo;I think this is a one hundred percent example of real private ownership and real technology entrepreneurship. It is a case where the owners treat their business like a real lifetime work. The work that delivers impressive results not only for the plant itself, not only for the region, but for the whole country. I honestly believe that launches of this scale are a step forward for the entire national chemical industry. And I&rsquo;m simply proud that we have partners of such class. They are real partners in every sense of the word, most notably from the standpoint of competence in engineering, finances, and even simple human reliability,&rdquo; noted the Chairman of the Executive Board of RUSNANO MC <strong>Anatoly Chubais</strong>.</p> Fri, 26 Aug 2016 12:00:00 +0300 RUSNANO Launches a Nuclear Medicine Center in Belgorod <h5>A modern and efficient method to diagnose cancers will become more available for residents of the Belgorod region. It is planned that more than 2,500&nbsp;people will be checked up at the center by the end of the year.</h5> <p>With the launch of the Belgorod positron-emission tomography center, high-tech medical aid on the diagnosis and treatment of cancers has become more accessible for region&#39;s residents. Most checkups will be conducted within the framework of the statutory health insurance program.</p> <p>&ldquo;A very important and long-awaited event has happened in the health system of the Belgorod region. The nuclear medicine center has been brought into operation. We are very grateful to RUSNANO&mdash;the initiator of this great project, which brings our healthcare to an absolutely new technological level. For many people, it means a good opportunity to be timely diagnosed and correctly treated. We completely understand how important it is today. Previously we used these services outside our region and sometimes abroad. Now it is available in our region,&rdquo; <strong>Evgeny Savсhenko, </strong>governor of the Belgorod region, said during the launch of the PET-center in Belgorod.</p> <p>RUSNANO is creating the first federal network of diagnostic Nuclear medicine centers on the Russian territory with private capital to increase the quality of diagnostics of the population. The project is implemented by portfolio company PET Technology.</p> <blockquote>PET/CT (positron-emission tomography / computer tomography) is one of the most modern and promising methods to identify cancers.</blockquote> <p>&ldquo;Sometimes we are reproached that out activities do not affect the lives of average people. We really work mostly in the B2B sector and a submersible pumps, carbon nanotubes, white metallurgy products will hardly impress a person not related to the business. And here, in Belgorod, we have an unambiguous and clear project helping people. It concerns a serious matter&mdash;cancers. Professionals say: the earlier diagnosed, the easier treated and cured. The essence of what has been built in Belgorod is to ensure early and super early diagnostics. It is a fundamental thing. It is a trend in the whole modern medicine&mdash;a shift from disease treatment to prevention. The PET-CT technology is the golden standard of diagnostics in oncology,&rdquo; <strong>Anatoly Chubais</strong>, Chairman of the Management Board of MC RUSNANO.</p> <p>The survival rate to a large extent depends on cancer stages at the moment of diagnostics. In case of cancer detected at stage I, the survival rate is more than 92%, stage II cancer is characterized by the 76% survival rate. In Russia, only a half of detected cancers is attributed to the first two stages. Positron-emission scanning coupled with computer tomography is the most modern and specific method of early cancer diagnostics today. This very method allows significantly increasing the survival rate of cancer patients.</p> <p>The most important PET/CT advantages include the possibility of diagnosing the disease at early stages; control the efficiency of chemical therapy and reduce its side effects; identify the prevalence stage of the disease to avoid unjustified surgery and related complications; accurately plan radiation therapy; diagnose disease recurrence.</p> <p>The first PET center of the network was launched in Ufa in the spring of 2014. Even now the PET Technology federal network includes 8 operating nuclear medicine centers in various regions (Elets, Tambov, Orel, Kursk, Lipetsk, Yekaterinburg, Moscow and Belgorod), efficient antitumor treatment using the CyberKnife radiosurgical system in Ufa, own production of radiopharmaceuticals for PET/CT in Elets and Ufa. Conditions to increase accessibility of advanced diagnostics are being created together with federal and regional legislative and executive bodies&mdash;95% of PET/CT checkups at Nuclear Medicine Centers of PET Technology Company are conducted under the statutory health insurance program. As of January 2017, more than 31 thousand persons where checked up in the federal network.</p> <h2>Technical Note</h2> <p>Positron-emission tomography (PET/CT) is the radionuclide tomography method of human internal organs examination. The method is based on recording pairs of gamma quanta arising when positrons are annihilated with electrons. Positrons emerge during the beta decay of a radionuclide, which is part of the radiopharmaceutical intravenously medicine injected into the body before the test and selectively accumulated in tumor tissues.</p> <p>This method is based on the possibility to track the distribution of biologically active compounds labelled with positron emitting radioisotopes in the body using special detection equipment (a PET scanner).</p> <p>Today, PET mostly uses positron emitting radioisotopes of elements of the second period of the periodic system, most frequently fluorine 18, with perfect characteristics for the use in PET: the largest half-life and the lowest radiation energy.</p> <p>The biological analogue of glucose&mdash;fluorodeoxyglucose (FDG), a molecule of which contains radioactive (positron emitting) nuclide fluorine 18 (18 FDG), is mostly used for positron-emission tomography. FDG is injected to a patient and then distributed in the whole body. Tumor cells much intensively consume glucose, which allows registering sides of pharmaceutical (FDG) accumulation&mdash;a congestion of tumor cells&mdash;with a PET scanner.</p> <p>To obtain fluorine-18, a cyclical medical cyclotron or (less frequently) a linear accelerator is used. The target is usually clean water or water enriched with Oxygen-18, which is subjected to proton bombardment. Oxygen-18, in turn, is made using low-temperature rectification.</p> Fri, 17 Mar 2017 12:00:00 +0300